Pentosan Polysulfate, An Anti-Viral Heparinoid, Prevents Severe Acute Respiratory Syndrome Corona Virus-2 Infection and Treats Symptoms of Long Coronavirus Disease PPS is a Anti-Viral Agent That Prevents SARS-CoV-2 infection
Main Article Content
Margaret M. Smith
James Melrose
http://orcid.org/0000-0001-9237-0524
http://orcid.org/0000-0001-9237-0524
Abstract
This study highlights the roles of pentosan polysulfate as a decoy anti-viral prophylactic that prevents severe acute respiratory syndrome coronavirus-2 infection. PPS also has multifunctional cell and tissue protective properties relevant to the treatment of the symptoms produced by long COVID disease. PPS has heparan sulfate (HS)-like properties, a key functional component of the lung glycocalyx. The glycocalyx is also rich in hyaluronan which has important cell shielding and cell regulatory properties. A healthy glycocalyx prevents access of viral particles to cell surface heparan sulfate-proteoglycans (syndecan, glypican) which act as viral receptors. Pentosan polysulfate promotes hyaluronan synthesis by many cell types, ensuring cells are surrounded by a healthy protective glycocalyx. Hyaluronan, however, has a relatively short biological half-life and is susceptible to degradation by hyaluronidases that are upregulated by inflammatory cytokines in acute respiratory distress syndrome in COVID-19 disease. This results in the glycocalyx becoming degraded and endothelial cells dysfunctional in COVID-19 disease. Prevention of viral interaction with the host cell surface intercepted by pentosan polysulfate, a decoy viral binding prophylactic agent, blocks viral interaction with cell-surface heparan sulfate, preventing viral interactions with other cell surface receptors such as neuropilin-1 and angiotensin-converting enzyme 2. Co-operation between heparan sulfate, neuropilin-1 and angiotensin-converting enzyme 2 facilitates the infection of host cells with severe acute respiratory syndrome coronavirus 2, thus if the initial interaction with heparan sulfate is blocked this prevents the subsequent viral interactive stages. Pentosan polysulfate also has multifunctional cell and tissue protective properties, broad anti-oxidant and anti-inflammatory properties and inhibits cytokine production in acute respiratory disease syndrome. Pentosan polysulfate inhibits p38 mitogen-activated protein kinase and nuclear factor-κB activation, reducing the production of pro-inflammatory cytokines such as tumor necrosis factor-α, interleukin-1β and interleukin-6. Furthermore, pentosan polysulfate is processed by enzymes of the gut microbiome into prebiotic xylo-oligosaccharides that preserve gut health and combat gut dysbiosis seen in COVID-19 disease. Studies are thus warranted to fully assess pentosan polysulfate as an anti-severe acute respiratory syndrome coronavirus-2 prophylactic agent and its multifunctional cell and tissue protective properties. Furthermore, from a practical and economic point of view, treatment with pentosan polysulfate would offer substantial cost-benefit advantages over conventional vaccine and antibiotic treatments and could also be used in an adjunctive capacity with existing therapies, offering flexibility in its use.
Keywords:
Pentosan polysulfate, SP54, Neuropilin-1, angiotensin-converting enzyme-2, Heparan sulfate, SARS-CoV-2, HIV, Herpes simplex, Dengue virus, Papillomavirus
Article Details
How to Cite
SMITH, Margaret M.; MELROSE, James.
Pentosan Polysulfate, An Anti-Viral Heparinoid, Prevents Severe Acute Respiratory Syndrome Corona Virus-2 Infection and Treats Symptoms of Long Coronavirus Disease.
Medical Research Archives, [S.l.], v. 13, n. 8, nov. 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6735>. Date accessed: 05 dec. 2025.
doi: https://doi.org/10.18103/mra.v13i8.6735.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1 Johnston, C., Hughes, H, Lingard, S, Hailey, S, Healy, B. Immunity and infectivity in covid-19. 378, e061402 (2022).
2 Yisimayi, A., et al., Repeated Omicron exposures override ancestral SARSCoV-2 immune imprinting. Nature 625, 148-156 (2024).
3 Cele, S., et al., Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654-656 (2022).
4 Kaku, Y., et al., Virological characteristics of the SARS-CoV-2 KP.2 variant. Lancet Infect Dis (2024).
5 Plante, J. A., et al., Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116-121 (2021).
6 Lopes-Pacheco, M., Silva, PL, Cruz, FF, Battaglini, D, Robba, C, Pelosi, P, Morales, MM, Caruso Neves, C, Rocco, PRM. Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. Front Physiol 12, 593223 (2021).
7 Mokhtari, T., Hassani, F, Ghaffari, N, Ebrahimi, B, Yarahmadi, A, Hassanzadeh, G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. J Mol Histol 51, 613-628 (2020).
8 Zaim, S., Chong, JH, Sankaranarayanan, V, Harky, A. COVID-19 and Multiorgan Response. Curr Probl Cardiol 45, 100618 (2020).
9 Narayanan, S., Jamison, DA, Guarnieri, JW et al. A comprehensive SARS-CoV-2 and COVID-19 review, Part 2: host extracellular to systemic effects of SARS-CoV-2 infection. Eur J Hum Genet 32, 10-20 (2024).
10 Tang, D., Comish ,P, Kang, R The hallmarks of COVID-19 disease. PLoS Pathog 16, e1008536 (2020).
11 Menon, N., Mohapatra, S. The COVID-19 pandemic: Virus transmission and risk assessment. Curr Opin Environ Sci Health 28, 100373 (2022).
12 Smith, M., Melrose, J. Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues. . Pharmaceuticals (Basel) 16, 437 (2023).
13 Smith, M., Hayes, AJ, Melrose, J. Pentosan Polysulfate, a Semisynthetic Heparinoid Disease-Modifying Osteoarthritic Drug with Roles in Intervertebral Disc Repair Biology Emulating the Stem Cell Instructive and Tissue Reparative Properties of Heparan Sulfate. Stem Cells Dev 31, 406-430. doi: 410.1089/scd.2022.0007 (2022).
14 Fehr, A., Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. Methoda Mol Biol 1282, 1-23 (2015).
15 Rabaan, A., Al-Ahmed,SH, Haque, S, Sah, R, Tiwari, R, Malik, YS, Dhama, K, Yatoo, MI, Bonilla-Aldana, DK, Rodriguez-Morales, AJ. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med 28, 174-184 (2020).
16 Rabaan, A., Al-Ahmed,SH, Haque, S, Sah, R, Tiwari, R, Malik, YS, Dhama, K, Yatoo, MI, Bonilla-Aldana, DK, Rodriguez-Morales, AJ. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med 28, 174-184 (2020).
17 Chafekar, A., Fielding, BC. MERS-CoV: understanding the latest human coronavirus threat. Viruses 10, 93 (2018).
18 Worldometer. Coronavirus death toll. https://http://www.worldometers.info/coronavirus/coronavirus-death-toll/ (2022).
19 Bhat, E., Khan, J, Sajjad, N, Ali, A, Aldakeel, FM, Mateen, A, Alqahtani, MS, Syed, R. SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis - An updated review. Int Immunopharmacol 95, 107493 (2021).
20 Guney, C., Akar, F. Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes. J Pharm Pharm Sci 24, 84-93 (2021).
21 Kim, S., Jin, W, Sood, A, Montgomery, DW, Grant, OC, Fuster, MM, Fu, L, Dordick, JS, Woods, RJ, Zhang, F, Linhardt, RJ. . Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res 181, 104873 (2020).
22 Rusnati, M., Urbinati, C, Caputo, A, Possati,L, Lortat-Jacob, H, Giacca, M, Ribatti, D, Presta, M. . Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem 276, 22420-22425 (2001).
23 Tandon, R., Sharp, JS, Zhang, F, Pomin, VH, Ashpole, NM, Mitra, D, McCandless, MG, Jin, W, Liu, H, Sharma, P, Linhardt, RJ. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. J Virol 95, e01987-01920 (2021).
24 Yu, M., Zhang, T, Zhang, W, Sun, Q, Li,H, Li, JP. Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins-An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic. Front Mol Biosci 7, 628551 (2021).
25 Schuurs, Z., Hammond, E, Elli, S, Rudd, TR, Mycroft-West, CJ, Lima, MA, Skidmore, MA, Karlsson, R, Chen, YH, Bagdonaite, I, Yang, Z, Ahmed, YA, Richard, DJ, Turnbull, J, Ferro, V, Coombe, DR, Gandhi, NS. . Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. Comput Struct Biotechnol J 19, 2806-2818 (2021).
26 Clausen, T., Sandoval, DR, Spliid, CB, Pihl, J, Painter, CD, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183, 1043-1057 (2020).
27 Partridge, L., Urwin, L, Nicklin, MJH, James, DC, Green, LR, Monk, PN. ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin. Cells 10, 1419 (2021).
28 Nie, C., Pouyan, P, Lauster, D, Trimpert, J, Kerkhoff, Y, Szekeres, GP, Wallert, M, Block, S, Sahoo, AK, Dernedde, J, Pagel,K, Kaufer, BB, Netz, RR, Ballauff, M, Haag, R. Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions*. Angew Chem Int Ed Engl 60, 15870-15878 (2021).
29 Kearns, F., Sandoval, DR, Casalino, L, Clausen, TM, Rosenfeld, MA, Spliid, CB, Amaro, RE, Esko, JD. Spike-heparan sulfate interactions in SARS-CoV-2 infection. Curr Opin Struct Biol 76, 102439 (2022).
30 Bhat, E., Khan, J, Sajjad, N, Ali, A, Aldakeel, FM, Mateen, A, Alqahtani, MS, Syed, R. SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis - An updated review. Int Immunopharmacol 95, 107493 (2021).
31 Guney, C., Akar, F. Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes. J Pharm Pharm Sci 24, 84-93 (2021).
32 Rusnati, M., Urbinati, C, Caputo, A, Possati,L, Lortat-Jacob, H, Giacca, M, Ribatti, D, Presta, M. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem 276, 22420-22425 (2001).
33 Tandon, R., Sharp, JS, Zhang, F, Pomin, VH, Ashpole, NM, Mitra, D, McCandless, MG, Jin, W, Liu, H, Sharma, P, Linhardt, RJ. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. J Virol 95, e01987-01920 (2021).
34 Yadav, R., Chaudhary, JK, Jain, N, Chaudhary, PK, Khanra, S, Dhamija, P, Sharma, A, Kumar, A, Handu, S. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells 10, 821 (2021).
35 Yuan, H., Wen,HL. Research progress on coronavirus S proteins and their receptors. . Arch Virol 28 (2021).
36 Mahmoud, I., Jarrar, YB. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges. Mol Biol Rep doi: 10.1007/s11033-021-06390-1 (2021).
37 Cantuti-Castelvetri, L., Ojha, R, Pedro, LD, Djannatian, M, Franz, J, Kuivanen, S, van der Meer, F, Kallio, K, Kaya, T, Anastasina, M, Smura, T, Levanov, L, Szirovicza, L, Tobi, A, Kallio-Kokko, H, Österlund, P, Joensuu, M, Meunier, FA, Butcher, SJ, Winkler, MS, Mollenhauer, B, Helenius, A, Gokce, O, Teesalu, T, Hepojoki, J, Vapalahti, O, Stadelmann, C, Balistreri, G, Simons, M. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370, 856-860 (2020).
38 Chekol Abebe, E., Mengie Ayele, T, Tilahun Muche, Z, Asmamaw Dejenie, T. . Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target. Biologics 15, 143-152 (2021).
39 Daly, J., Simonetti, B, Klein, K, Chen, KE, Williamson, MK, Antón-Plágaro, C, Shoemark, DK, Simón-Gracia, L, Bauer, M, Hollandi, R, Greber, UF, Horvath, P, Sessions, RB, Helenius, A, Hiscox, JA, Teesalu, T, Matthews, DA, Davidson, AD, Collins, BM, Cullen, PJ, Yamauchi, Y. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science 370, 861-865 (2020).
40 Sajuthi, S., DeFord, P, Li, Y, Jackson, ND, Montgomery, MT, Everman, JL, Rios, CL, Pruesse, E, Nolin, JD, Plender, EG, Wechsler, ME, Mak, ACY, Eng, C, Salazar, S, Medina, V, Wohlford, EM, Huntsman, S, Nickerson, DA, Germer, S, Zody, MC, Abecasis, G, Kang, HM, Rice, KM, Kumar, R, Oh, S, Rodriguez-Santana, J, Burchard, EG, Seibold, MA. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. . Nat Commun 11, 5139 (2020).
41 Zmora, P., Moldenhauer, AS, Hofmann-Winkler, H, Pöhlmann, S. TMPRSS2 Isoform 1 Activates Respiratory Viruses and Is Expressed in Viral Target Cells. . PLoS One 10, e0138380 (2015).
42 Bertram, S., Glowacka, I, Steffen, I, Kühl, A, Pöhlmann, S Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev Med Virol 20, 298-310 (2010).
43 Bertram, S., Glowacka, I, Blazejewska, P, Soilleux, E, Allen, P, Danisch, S, et al. . . TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. . J Virol 84, 10016-10025 (2010).
44 Muralidar, S., Gopal, G, Visaga, Ambi, S. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19. J Med Virol doi: 10.1002/jmv.27019 (2021).
45 Davies, J., Randeva, HS, Chatha, K, Hall, M, Spandidos, DA, Karteris, E, Kyrou, I. . Neuropilin 1 as a new potential SARS CoV 2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID 19. Mol Med Rep 22, 4221-4226 (2020).
46 Berrou, E., Quarck, R, Fontenay-Roupie, M, Lévy-Toledano, S, Tobelem, G, Bryckaert, M. Transforming growth factor-beta 1 increases internalization of basic fibroblast growth factor by smooth muscle cells: implication of cell-surface heparan sulphate proteoglycan endocytosis. Biochem J 311, 393-399 (1995).
47 Christianson, H., Belting, M. . Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biol 35, 51-55 (2014).
48 Neill, T., Schaefer, L, Iozzo, RV. Decoding the Matrix: Instructive Roles of Proteoglycan Receptors. Biochemistry 54, 4583-4598 (2015).
49 Balistreri, G., Yamauchi, Y, Teesalu, T. A widespread viral entry mechanism: The C-end Rule motif-neuropilin receptor interaction. Proc Natl Acad Sci USA 118, e2112457118 (2021).
50 Danthi, P., Holm, GH, Stehle, T, Dermody, TS. Reovirus receptors, cell entry, and proapoptotic signaling. Adv Exp Med Biol 790, 42-71 (2013).
51 Inoue, J., Ninomiya, M, Shimosegawa, T, McNiven, MA. Cellular Membrane Trafficking Machineries Used by the Hepatitis Viruses. Hepatology 68, 751-762 (2018).
52 Mikuličić, S., Florin, L. The endocytic trafficking pathway of oncogenic papillomaviruses. Papillomavirus Res 7, 135-137 (2019).
53 Perera-Lecoin, M., Meertens, L, Carnec, X, Amara, A. Flavivirus entry receptors: an update. Viruses 6, 69-88 (2013).
54 Altgärde, N., Eriksson, C, Peerboom, N, Block, S, Altgärde, N, Wahlsten, O, Möller, S, Schnabelrauch, M, Trybala, E, Bergström, T, Bally, M. Binding Kinetics and Lateral Mobility of HSV-1 on End-Grafted Sulfated Glycosaminoglycans. Biophys J 113, 1223-1234 (2017).
55 Egedal, J., Xie, G, Packard, TA, Laustsen, A, Neidleman, J, Georgiou, K, Pillai, SK, Greene, WC, Jakobsen, MR, Roan, NR. . Hyaluronic acid is a negative regulator of mucosal fibroblast-mediated enhancement of HIV infection. Mucosal Immunol 14, 1203-1213 (2021).
56 Li, P., Fujimoto, K, Bourguingnon, L, Yukl, S, Deeks, S, Wong, JK. Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4(+) T cells. Immunol Cell Biol 92, 770-780 (2014).
57 Peerboom, N., Phan-Xuan, T, Moeller, S, Schnabelrauch, M, Svedhem, S, Trybala, E, Bergström, T, Bally, M. Mucin-like Region of Herpes Simplex Virus Type 1 Attachment Protein Glycoprotein C (gC) Modulates the Virus-Glycosaminoglycan Interaction. J Biol Chem 290, 21473-21485 (2015).
58 Turville, S. Blocking of HIV entry through CD44-hyaluronic acid interactions. Immunol Cell Biol 92, 735-736 (2014).
59 Smith, M., Melrose, J. Impaired instructive and protective barrier functions of the endothelial cell glycocalyx pericellular matrix is impacted in COVID-19 disease. J Cell Mol Med 28, e70033. doi: 70010.71111/jcmm.70033. (2024).
60 Libby, P., and Luscher, T. COVID-19 is, in the end, an endothelial disease. Eur Heart J 41, 3038-3044 (2020).
61 Yang, J., LeBlanc, ME, Cano, I, Saez-Torres, KL, Saint-Geniez, M, Ng, YS, et al. . ADAM10 and ADAM17 proteases mediate proinflammatory cytokine-induced and constitutive cleavage of endomucin from the endothelial surface. J Biol Chem 295, 6641-6651 (2020).
62 Baggen, J. e. a. Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nat Genet https://doi.org/10.1038/s41588-021-00805-2 (2021).
63 Liu, L., Chopra, P, Li, X, Bouwman, KM, Tompkins, SM, Wolfert, MA, de Vries, RP, Boons, GJ. Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2. ACS Cent Sci 7, 1009-1018 (2021).
64 Zhang, Q. e. a. Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov 6, 80 (2020).
65 Bao, L. e. a. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830-833 (2020).
66 Hoffmann, M. e. a. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell https://doi.org/10.1016/j.cell.2020.02.052 (2020).
67 Lan, J. e. a. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215-220 (2020).
68 Schneider, W. e. a. Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. Cell 184, 120-132 (2021).
69 Sun, S. e. a. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124-133 (2020).
70 Zhou, P. e. a. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273 (2020).
71 Balistreri, G., Yamauchi, Y, Teesalu, T. A widespread viral entry mechanism: The C-end Rule motif-neuropilin receptor interaction. . Proc Natl Acad Sci USA 118, e2112457118 (2021).
72 Cantuti-Castelvetri, L., Ojha, R, Pedro, LD, Djannatian, M, Franz, J, Kuivanen, S, van der Meer, F, Kallio, K, Kaya, T, Anastasina, M, Smura, T, Levanov, L, Szirovicza, L, Tobi, A, Kallio-Kokko, H, Österlund, P, Joensuu, M, Meunier, FA, Butcher, SJ, Winkler, MS, Mollenhauer, B, Helenius, A, Gokce, O, Teesalu, T, Hepojoki, J, Vapalahti, O, Stadelmann, C, Balistreri, G, Simons, M. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370, 856-860 (2020).
73 Shi, Q., Jiang, J, Luo, G. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J Virol 87, 6866-6875. doi: 6810.1128/JVI.03475-03412. (2013).
74 Okamoto, K., Kinoshita, H, Parquet, MDC, Raekiansyah, M, Kimura, D, Yui, K, et al Dengue virus strain DEN2 16681 utilizes a specific glycochain of syndecan-2 proteoglycan as a receptor. J Gen Virol 93, 761-770. doi: 710.1099/ vir.1090.037853-037850. (2012).
75 Tripathi, S., Li, Y, Luo, G. Syndecan 2 proteoglycan serves as a hepatitis B virus cell attachment receptor. J Virol e0079625. doi: 10.1128/jvi.00796-25 (2025).
76 de Witte, L., Bobardt, M, Chatterji, U, Degeest, G, David, G, Geijtenbeek, TB, Gallay, P. . Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci U S A 104, 19464-19469. doi: 19410.11073/pnas.0703747104. (2007).
77 Hudák, A., Roach, M, Pusztai, D, Pettkó-Szandtner, A, Letoha, A, Szilák, L, et al Syndecan-4 Mediates the Cellular Entry of Adeno-Associated Virus 9. Int J Mol Sci 24, 3141. doi: 3110.3390 /ijms24043141. (2023).
78 Wang, R., Wang, X, Ni, B, Huan, CC, Wu, JQ, Wen, LB, et al Syndecan-4, a PRRSV attachment factor, mediates PRRSV entry through its interaction with EGFR. . Biochem Biophys Res Commun 475, 230-237. doi: 210.1016/j.bbrc.2016 .1005.1084. (2016).
79 Verrier, E., Colpitts, CC, Bach, C, Heydmann, L, Weiss, A, Renaud, M, et al. . A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. Hepatology 63, 35-48. doi: 10.1002 /hep.28013. (2016).
80 Hu, S., Zhao, K, Lan, Y, Shi, J, Guan, J, Lu, H, et al Cell-surface glycans act as attachment factors for porcine hemagglutinating encephalomyelitis virus. Vet Microbiol 265, 109315. doi: 109310.1010 16/j.vetmic.102021.109315. (2022).
81 Shafti-Keramat, S., Handisurya, A, Kriehuber, E, Meneguzzi, G, Slupetzky, K, Kirnbauer, R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77, 13125-13135. doi: 13110.11128/jvi.13177 .13124.13125-13135.12003 (2003).
82 Shafti-Keramat, S., Handisurya, A, Kriehuber, E, Meneguzzi, G, Slupetzky, K, Kirnbauer, R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77, 13125-13135. doi: 13110.11128/jvi.13177 .13124.13125-13135.12003. (2003).
83 Bermejo-Jambrina, M., Eder, J, Kaptein, TM, van Hamme, JL, Helgers, LC, Vlaming, KE, et al Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. . EMBO J 40, e106765. doi: 106710.115252/embj.2020106765 (2021).
84 Gallay, P. Syndecans and HIV-1 pathogenesis. Microbes Infect 6, 617-622. doi: 610.1016/j.micinf .2004.1002.1004. (2004).
85 Bobardt , M., Saphire, AC, Hung, HC, Yu, X, Van der Schueren, B, Zhang, Z, et al Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 18, 27-39. doi: 10.1016/s1 074-7613(1002)00504-00506. (2003).
86 Saphire, A., Bobardt, MD, Zhang, Z, David, G, Gallay, PA. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol 75, :9187-9200. doi: 9110.1128/JVI.9175.9119.9187-9200.2001. (2001).
87 Chhabra, M., Shanthamurthy, CD, Kumar ,NV, Mardhekar, S, Vishweshwara, SS, Wimmer, N, Modhiran, N, Watterson, D, Amarilla, AA, Cha, JS, Beckett, JR, De Voss, JJ, Kayal, Y, Vlodavsky, I, Dorsett ,LR, Smith, RAA, Gandhi, NS, Kikkeri, R, Ferro, V. Amphiphilic Heparinoids as Potent Antiviral Agents against SARS-CoV-2. J Med Chem 67, 11885-11916. doi: 11810.11021/acs.jmedche m.11884c00487. (2024).
88 De Clercq, E. Potential drugs for the treatment of AIDS. J Antimicrob Chemother 23 Suppl A, 35-46. doi: 10.1093/jac/1023.suppl_a.1035 (1989).
89 Vert, M. The non-specific antiviral activity of polysulfates to fight SARS-CoV-2, its mutants and viruses with cationic spikes. J Biomater Sci Polym Ed 32, 1466-1471. doi: 1410.1080/09205063.0920 2021.01925391. (2021).
90 Pavan, M., Fanti ,CD, Lucia, AD, Canato, E, Acquasaliente, L, Sonvico, F, Delgado, J, Hicks. A, Torrelles, JB, Kulkarni ,V, Dwivedi ,V, Zanellato, AM, Galesso, D, Pasut, G, Buttini, F, Martinez-Sobrido, L, Guarise, C. Aerosolized sulfated hyaluronan derivatives prolong the survival of K18 ACE2 mice infected with a lethal dose of SARS-CoV-2. Eur J Pharm Sci 187, 106489. doi: 106410. 101016/j.ejps.102023.106489. (2023).
91 Baba, M., Nakajima, M, Schols, D, Pauwels, R, Balzarini, J, De Clercq, E. . Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res 9, 335-343. doi: 310.1016/0166-3542(1088)90035-90036. (1988).
92 Rusnati, M., Urbinati, C, Caputo, A, Possati, L, Lortat-Jacob, H, Giacca, M, Ribatti, D, Presta, M. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem 276, 22420-22425 (2001).
93 Biesert, L., Suhartono, H, Winkler, I, Meichsner, C, Helsberg, M, Hewlett, G, Klimetzek, V, Mölling, K, Schlumberger, HD, Schrinner, E, et al. Inhibition of HIV and virus replication by polysulphated polyxylan: HOE/BAY 946, a new antiviral compound. AIDS 2, 449-457. doi: 410.109 7/00002030-198812000-198800007. (1988).
94 Biesert , L., Adamski, M, Zimmer, G, Suhartono, H, Fuchs, J, Unkelbach, U, Mehlhorn, RJ, Hideg, K, Milbradt, R, Rübsamen-Waigmann, H. . Anti-human immunodeficiency virus (HIV) drug HOE/BAY946 increases membrane hydrophobicity of human lymphocytes and specifically suppresses HIV-protein synthesis. Med Microbiol Immunol 179, 307-321. doi: 310.1007/BF00189609. (1990).
95 von Briesen, H., Meichsner ,C, Andreesen, R, Esser, R, Schrinner, E, Rübsamen-Waigmann, H. . The polysulphated polyxylan Hoe/Bay-946 inhibits HIV replication on human monocytes/macrophage s. Res Virol 141, 251-257. doi: 210.1016/0923-2516(1090)90029-i. (1990).
96 Peters, M., Witvrouw, M, De Clercq, E, Ruf, B. Pharmacokinetics of intravenous pentosan polysulphate (HOE/BAY 946) in HIV-positive patients. AIDS 5, 1534-1535. doi: 1510.1097/000 02030-199112000-199100021. (1991).
97 Pearce-Pratt, R., Phillips, DM. . Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 54, 173-182. doi: 110.1095/biolreprod 1054.1091.1173. (1996).
98 Witvrouw, M., Desmyter, J, De Clercq, E. . Antiviral portrait series: 4. Polysulfates as inhibitors of HIV and other enveloped viruses. . Antiviral Chemistry & ChemotherapY 5, 345-359 (1994).
99 Jurkiewicz E, P. P., Jentsch KD, Hartmann H, Hunsmann G. In vitro anti-HIV-1 activity of chondroitin polysulphate. AIDS. 3, 423-427. doi: 410.1097/00002030-198907000-198900003. (1989).
100 Vanderlinden, E., Boonen, A, Noppen, S, Schoofs, G, Imbrechts, M, Geukens, N, Snoeck, R, Stevaert ,A, Naesens, L, Andrei ,G, Schols, D. PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding. Antiviral Res 217, 105700. doi: 105710.101016/j.antiviral.10 2023.105700. (2023).
101 Huskens, D., Profy, AT, Vermeire, K, Schols, D. PRO 2000, a broadly active anti-HIV sulfonated compound, inhibits viral entry by multiple mechanisms. Retrovirology 7 Suppl 1, P17. doi: 10.1186/1742-4690-1187-S1181-P1117 (2010).
102 Nakamura, T., Satoh, K, Fukuda, T, Kinoshita, I, Nishiura, Y, Nagasato, K, Yamauchi, A, Kataoka, Y, Nakamura, T, Sasaki, H, Kumagai, K, Niwa, M, Noguchi, M, Nakamura, H, Nishida, N, Kawakami, A. Pentosan polysulfate treatment ameliorates motor function with increased serum soluble vascular cell adhesion molecule-1 in HTLV-1-associated neurologic disease. J Neurovirol 20, 269-277. doi: 210.1007/s13365-13014-10244-13368. (2014).
103 Callaway, E. Heavily mutated Omicron variant puts scientists on alert. Nature 600, 21 (2021).
104 WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern. (2021).
105 Smith, M., Melrose, J. . Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues. Pharmaceuticals (Basel). 16, 437 (2023).
106 GISAID. https://www.gisaid.org/hcov19-variants/. (2021).
107 Basheer, A., Zahoor, I, Yaqub, T. . Genomic architecture and evolutionary relationship of BA.2.75: A Centaurus subvariant of Omicron SARS-CoV-2. PLoS One 18, e0281159. doi: 0281110.0 281371/journal.pone.0281159. (2023).
108 Caputo, E., Mandrich, L. SARS-CoV-2: Searching for the Missing Variants. Viruses 14, 2364. doi: 2310.3390/v14112364. (2022).
109 Zappa, M., Verdecchia, P, Angeli, F. Knowing the new Omicron BA.2.75 variant ('Centaurus'): A simulation study. Eur J Intern Med 105, 107-108. doi: 110.1016/j.ejim.2022.1008.1009. (2022).
110 Sabbatucci, M., Vitiello, A, Clemente, S, Zovi, A, Boccellino, M, Ferrara, F, Cimmino, C, Langella, R, Ponzo, A, Stefanelli, P, Rezza, G. . Omicron variant evolution on vaccines and monoclonal antibodies. Inflammopharmacology 31, 1779-1788 . doi: 1710.1007/s10787-10023-01253-10786 (2023).
111 Fernandes, Q., Inchakalody, VP, Merhi, M, Mestiri, S, Taib, N, Moustafa, Abo El-Ella, D, Bedhiafi, T, Raza, A, Al-Zaidan, L, Mohsen, MO, Yousuf Al-Nesf, MA, Hssain, AA, Yassine, HM, Bachmann, MF, Uddin, S, Dermime, S. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med 54, 524-540 (2022).
112 Dechecchi, M., Tamanini, A, Bonizzato, A, Cabrini, G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 268, 382-390 (2000).
113 Lerch, T., Chapman, MS. . Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). . Virology 423, 6-13 (2012).
114 Qiu, J., Handa, A, Kirby, M, Brown, KE. . The interaction of heparin sulfate and adeno-associated virus 2. Virology 269, 137-147 (2000).
115 Murakami, S., Takenaka-Uema, A, Kobayashi,T, Kato, K, Shimojima, M, Palmarini, M, Horimoto, T. Heparan Sulfate Proteoglycan Is an Important Attachment Factor for Cell Entry of Akabane and Schmallenberg Viruses. J Virol 91, pii: e00503-00517 (2017).
116 McAllister , N., Liu, Y, Silva, LM, Lentscher, AJ, Chai, W, Wu, N, Griswold, KA, Raghunathan, K, Vang, L, Alexander ,J, Warfield, KL, Diamond, MS, Feizi,T, Silva, LA, Dermody, TS. Chikungunya Virus Strains from Each Genetic Clade Bind Sulfated Glycosaminoglycans as Attachment Factors. J Virol 94, e01500-01520. (2020).
117 Merilahti, P., Karelehto, E, Susi, P. Role of Heparan Sulfate in Cellular Infection of Integrin-Binding Coxsackievirus A9 and Human Parechovirus 1 Isolates. . PLoS One 11, e0147168 (2016).
118 Pourianfar , H., Kirk, K, Grollo, L. Initial evidence on differences among Enterovirus 71, Coxsackievirus A16 and Coxsackievirus B4 in binding to cell surface heparan sulphate. Virusdisease 25, 277-284 (2014).
119 Zautner, A., Jahn, B, Hammerschmidt, E, Wutzler, P, Schmidtke, M. N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J Virol 80, 6629-6636 (2006).
120 Artpradit, C., Robinson, LN, Gavrilov, BK, Rurak, TT, Ruchirawat, M, Sasisekharan, R. Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles. Virus Res 176, 69-77 (2013).
121 Hilgard, P., Stockert, R. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 32, 1069-1077 (2000).
122 Saksono, B., Dewi, BE, Nainggolan, L, Suda, Y. A Highly Sensitive Diagnostic System for Detecting Dengue Viruses Using the Interaction between a Sulfated Sugar Chain and a Virion. PLoS One 10, e0123981 (2015).
123 Wu, S., Wu, Z, Wu, Y, Wang, T, Wang, M, Jia, R, Zhu, D, Liu, M, Zhao, X, Yang, Q, Wu, Y, Zhang, S, Liu, Y, Zhang, L, Yu, Y, Pan, L, Chen, S, Cheng, A. . Heparin sulfate is the attachment factor of duck Tembus virus on both BHK21 and DEF cells. Virol J 16, 134 (2019).
124 Tamhankar, M., Gerhardt, DM, Bennett, RS, Murphy, N, Jahrling, PB, Patterson, JL. Heparan sulfate is an important mediator of Ebola virus infection in polarized epithelial cells. Virol J 15, 135 (2018).
125 Israelsson, S., Gullberg, M, Jonsson, N, Roivainen, M, Edman, K, Lindberg, AM. Studies of Echovirus 5 interactions with the cell surface: heparan sulfate mediates attachment to the host cell. Virus Res 151, 170-176 (2010).
126 Tan, C., Poh, CL, Sam, IC, Chan, YF. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. . J Virol 87, 611-620 (2013).
127 Tan, C., Sam, IC, Lee, VS, Wong, HV, Chan, YF. VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology 501, 79-87 (2017).
128 Salvador, B., Sexton, NR, Carrion, R Jr, Nunneley, J, Patterson, JL, Steffen, I, Lu, K, Muench, MO, Lembo, D, Simmons, G. . Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol 87, 3295-3304 (2013).
129 Mathieu, C., Dhondt, KP, Châlons, M, Mély, S, Raoul, H, Negre, D, Cosset, FL, Gerlier, D, Vivès, RR, Horvat, B. Heparan sulfate-dependent enhancement of henipavirus infection. mBio 6, e02427 (2015).
130 Schulze, A., Gripon, P, Urban, S. . Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 16, 1759-1766 (2007).
131 Lamas Longarela, O., Schmidt, TT, Schöneweis, K, Romeo, R, Wedemeyer, H, Urban, S, Schulze, A. P. Proteoglycans act as cellular hepatitis delta virus attachment receptors. . PLoS One 8, e58340 (2013).
132 Olenina, L., Kuzmina, TI, Sobolev, BN, Kuraeva, TE, Kolesanova, EF, Archakov, AI. . Identification of glycosaminoglycan-binding sites within hepatitis C virus envelope glycoprotein E2. . J Viral Hepat 12, 584-593 (2005).
133 Xu, Y., Martinez, P, Séron, K, Luo, G, Allain, F, Dubuisson, J, Belouzard, S. Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans. J Virol 89, 3846-3858 (2015).
134 Akula, S., Pramod, NP, Wang, FZ, Chandran, B. Human herpesvirus 8 envelope-associated glycoprotein B interacts with heparan sulfate-like moieties. Virology 284, 235-249 (2001).
135 Feyzi, E., Trybala, E, Bergström, T, Lindahl, U, Spillmann, D. . Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C. J Biol Chem 372, 24850-24857 (1997).
136 Thammawat, S., Sadlon, TA, Hallsworth, PG, Gordon, DL. . Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection. J Virol 82, 11767-11774 (2008).
137 Karasneh, G., Ali,M, Shukla, D. . An important role for syndecan-1 in herpes simplex virus type-1 induced cell-to-cell fusion and virus spread. PLoS One 6, e25252 (2011).
138 Terry-Allison, T., Montgomery, RI, Warner, MS, Geraghty, RJ, Spear, PG. Contributions of gD receptors and glycosaminoglycan sulfation to cell fusion mediated by herpes simplex virus 1. Virus Res 74, 39-45 (2001).
139 Connell, B. a. L.-J., H. Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibition. Frontiers in Immunology 4, 385 (2013).
140 Guibinga, G., Miyanohara, A, Esko, JD, Friedmann, T. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther 5, 538-546 (2002).
141 Trkola, A., Gordon, C, Matthews, J, Maxwell, E, Ketas, T, Czaplewski ,L, Proudfoot, AE, Moore, JP. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. J Virol 73, 6370-6379 (1999).
142 Nasimuzzaman, M., Persons, DA. Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells. Mol Ther. 2012 Jun;20(6):1158-66. Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells. Mol Ther 20, 1158-1166 (2012).
143 Plochmann, K., Horn, A, Gschmack, E, Armbruster, N, Krieg, J, Wiktorowicz, T, Weber, C, Stirnnagel, K, Lindemann, D, Rethwilm, A, Scheller, C. Heparan sulfate is an attachment factor for foamy virus entry. J Virol 86, 10028-10035 (2012).
144 Bousarghin, L., Hubert, P, Franzen, E, Jacobs, N, Boniver, J, Delvenne, P. Human papillomavirus 16 virus-like particles use heparan sulfates to bind dendritic cells and colocalize with langerin in Langerhans cells. J Gen Virol 86, 1297-1305 (2005).
145 Feldman, S., Audet, S, Beeler, JA. . The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol 74, 6442-6447 (2000).
146 Chang, A., Masante, C, Buchholz, UJ, Dutch, RE. Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. J Virol 86, 3230-3243 (2012).
147 Su, C., Liao, CL, Lee, YL, Lin, YL. Highly sulfated forms of heparin sulfate are involved in japanese encephalitis virus infection. Virology 286, 206-215 (2001).
148 Chowalter, R., Pastrana, DV, Buck, CB. Glycosaminoglycans and sialylated glycans sequentially facilitate Merkel cell polyomavirus infectious entry. PLoS Pathog 7, e1002161 (2011).
149 Kureishy, N., Faruque, D, Porter, CD. Primary attachment of murine leukaemia virus vector mediated by particle-associated heparan sulfate proteoglycan. Biochem J 400, 421-430 (2006).
150 Gillet , L., Adler, H, Stevenson ,PG. Glycosaminoglycan interactions in murine gammaherpesvirus-68 infection. PLoS One 2, e347 (2007).
151 Huan, C., Wang, Y, Ni, B, Wang, R, Huang, L, Ren, XF, Tong, GZ, Ding, C, Fan, HJ, Mao, X. Porcine epidemic diarrhea virus uses cell-surface heparan sulfate as an attachment factor. . Arch Virol 160, 1621-1628 (2015).
152 Trybala, E., Bergström, T, Spillmann, D, Svennerholm, B, Olofsson, S, Flynn, SJ, Ryan, P. Mode of interaction between pseudorabies virus and heparan sulfate/ heparin. Virology 218, 35-42 (1996).
153 Sasaki, M., Anindita, PD, Ito, N, Sugiyama, M, Carr, M, Fukuhara, H, Ose, T, Maenaka, K, Takada, A, Hall, WW, Orba, Y, Sawa, H. The Role of Heparan Sulfate Proteoglycans as an Attachment Factor for Rabies Virus Entry and Infection. J Infect Dis 217, 1740-1749 (2018).
154 Hallak, L., Spillmann, D, Collins, PL, Peeples, ME. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 74, 10508-10513 (2000).
155 Shields, B., Mills, J, Ghildyal, R, Gooley, P, Meanger, J. Multiple heparin binding domains of respiratory syncytial virus G mediate binding to mammalian cells. Arch Virol 148, 1987-2003 (2003).
156 Ennemoser, M., Rieger, J, Muttenthaler, E, Gerlza, T, Zatloukal, K, Kungl, AJ. Enoxaparin and pentosan polysulfate bind to the SARS-CoV-2 spike protein and human ACE2 receptor, inhibiting Vero cell infection. Biomedicines 10, 49 (2022).
157 Escribano-Romero, E., Jimenez-Clavero, MA, Gomes, P, García-Ranea, JA, Ley, V. Heparan sulphate mediates swine vesicular disease virus attachment to the host cell. J Gen Virol 85, 653-663 (2004).
158 Byrnes, A., Griffin, DE. Binding of Sindbis virus to cell surface heparan sulfate. J Virol 72, 7349-7356 (1998).
159 Hulst, M., van Gennip, HG, Moormann, RJ. . Passage of classical swine fever virus in cultured swine kidney cells selects virus variants that bind to heparan sulfate due to a single amino acid change in envelope protein E(rns). J Virol 74, 9553-9561 (2000).
160 Luteijn, R., van Diemen, F, Blomen, VA, Boer, IGJ, Manikam Sadasivam, S, van Kuppevelt, TH, Drexler, I, Brummelkamp, TR, Lebbink, RJ, Wiertz, EJ. . A Genome-Wide Haploid Genetic Screen Identifies Heparan Sulfate-Associated Genes and the Macropinocytosis Modulator TMED10 as Factors Supporting Vaccinia Virus Infection. J Virol 93, e02160-02118 (2019).
161 Tan, C., Sam, IC, Chong, WL, Lee, VS, Chan, YF. Polysulfonate suramin inhibits Zika virus infection. Antiviral Res 143, 186-194 (2017).
162 García-Villalón, D., Gil-Fernández, C. . Antiviral activity of sulfated polysaccharides against African swine fever virus. Antiviral Res 15, 139-148 (1991).
163 Baba, M., Snoeck, R, Pauwels, R, de Clercq, E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 32, 1742-1745 (1988).
164 Baba, M., Nakajima, M, Schols, D, Pauwels, R, Balzarini, J, De Clercq, E. . Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res 9, 335-343 (1988).
165 Ma, G., Yasunaga, JI, Ohshima, K, Matsumoto, T, Matsuoka, M. Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 Activities In Vitro and In Vivo. J Virol 93, e00413-00419 (2019).
166 Herrero, L., Foo, SS, Sheng, KC, Chen, W, Forwood, MR, Bucala, R, Mahalingam, S. Pentosan Polysulfate: a Novel Glycosaminoglycan-Like Molecule for Effective Treatment of Alphavirus -Induced Cartilage Destruction and Inflammatory Disease. J Virol 89, 8063-8076 (2015).
167 Krishnan, R., Duiker, M, Rudd, PA, Skerrett, D, Pollard, JGD, Siddel, C, Rifat, R, Ng, JHK, Georgius, P, Hererro, LJ, Griffin, P. Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study. BMC Musculoskelet Disord 22, 271 (2021).
168 Tavares-Júnior, J., de Souza, ACC, Borges, JWP, Oliveira, DN, Siqueira-Neto, JI, Sobreira-Neto, MA, Braga-Neto, P. COVID-19 associated cognitive impairment: A systematic review. . Cortex 152, 77-97 (2022).
169 Kumagai, K., Shirabe, S, Miyata, N, Murata, M, Yamauchi, A, Kataoka, Y, Niwa, M. Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis--an open clinical trial. BMC Clin Pharmacol 10, 7. doi: 10.1186/1472-6904-1110-1187. (2010).
170 Eita, M., Ashour, RH, El-Khawaga, OY. . Pentosan polysulfate exerts anti-inflammatory effect and halts albuminuria progression in diabetic nephropathy: Role of combined losartan. . Fundam Clin Pharmacol 36, 801-810. doi: 810.1111/ fcp.12781 (2022).
171 Rudd, P., Lim, EXY, Stapledon, CJM, Krishnan, R, Herrero, LJ. Pentosan polysulfate sodium prevents functional decline in chikungunya infected mice by modulating growth factor signalling and lymphocyte activation. PLoS ONE 16, e0255125 (2021).
172 Krishnan, R., Stapledon, CJM, Mostafavi, H, Freitas, JR, Liu, X, Mahalingam, S, Zaid, A. Anti-inflammatory actions of Pentosan polysulfate sodium in a mouse model of influenza virus A/PR8/34-induced pulmonary inflammation. Front Immunol 14, 1030879. doi: 1030810.103338 9/fimmu.1032023.1030879 (2023).
173 Bertini, S., Alekseeva, A, Elli, S, Pagani, I, Zanzoni, S, Eisele, G, Krishnan, R, Maag, KP, Reiter, C, Lenhart, D, Gruber, R, Yates, EA, Vicenzi, E, Naggi, A, Bisio, A, Guerrin,i M. Pentosan Polysulfate Inhibits Attachment and Infection by SARS-CoV-2 In Vitro: Insights into Structural Requirements for Binding. . Thromb Haemost 122, 984-997. doi: 910.1055/a-1807-0168 (2022).
174 Wool, G., Miller, JL. . The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology 88, 15-27, doi:doi: 10.1159/000512007. (2021).
175 Iba, T., Levy, JH, Levi ,M, Thachil, J. Coagulopathy in COVID-19. J Thromb Haemost 18, 2103-2109, doi:doi: 10.1111/jth.14975 (2020).
176 Grobler, C., Maphumulo, SC, Grobbelaar, LM, Bredenkamp, JC, Laubscher, GJ, Lourens, PJ, Steenkamp, J, Kell, DB, Pretorius, E. Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes. Int J Mol Sci 21, 5168, doi: doi: 10.3390/ijms21145168. (2020).
177 Vögtle, T., Sharma, S, Mori, J, Nagy, Z, Semeniak, D, Scandola, C, Geer, MJ, Smith, CW, Lane, J, Pollack, S, Lassila, R, Jouppila, A, Barr, AJ, Ogg, DJ, Howard, TD, McMiken, HJ, Warwicker, J, Geh C, Rowlinson, R, Abbott ,WM, Eckly, A, Schulze, H, Wright ,GJ, Mazharian, A, Fütterer, K, Rajesh, S, Douglas, MR, Senis, YA. Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B. . Elife 8, e46840 (2019).
178 Koupenova, M., Corkrey, HA, Vitseva, O, Tanriverdi, K, Somasundaran, M, Liu, P, Soofi, S, Bhandari, R, Godwin, M, Parsi, KM, Cousineau, A, Maehr, R, Wang, JP, Cameron, SJ, Rade, J, Finberg, RW, Freedman, JE. SARS-CoV-2 Initiates Programmed Cell Death in Platelets. Circ Res 129, 631-646 (2021).
179 Lord, M., Tang, F, Rnjak-Kovacina, J, Smith, JGW, Melrose, J, Whitelock ,JM. . The multifaceted roles of perlecan in fibrosis. . Matrix Biol 68-69, 150-166 (2018).
180 Lord, M., Chuang, CY, Melrose, J, Davies, MJ, Iozzo, RV, Whitelock, JM. . The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling. Matrix Biol 35, 112-122 (2014).
181 Whitelock, J., Melrose, J, Iozzo ,RV. Diverse cell signaling events modulated by perlecan. Biochemistry 47, 11174-11183 (2008).
182 Hayashida, K., Aquino, RS, Park, PW. Coreceptor functions of cell surface heparan sulfate proteoglycans. Am J Physiol Cell Physiol 322, C896-C912 (2022).
183 Smits , N., Shworak ,NW, Dekhuijzen, PN, van Kuppevelt ,TH. Heparan sulfates in the lung: structure, diversity, and role in pulmonary emphysema. Anat Rec (Hoboken) 293, 955-967 (2010).
184 Burgess, J., Mauad, T, Tjin, G, Karlsson, JC, Westergren-Thorsson, G. The extracellular matrix - the under-recognized element in lung disease? J Pathol 240, 397-409 (2016).
185 Burgstaller, G., Oehrle, B, Gerckens, M, White, ES, Schiller, HB, Eickelberg, O. The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. . Eur Respir J 50, 1601805 (2017).
186 Zhou, Y., Horowitz ,JC, Naba, A, Ambalavanan, N, Atabai,, K, Balestrini J, Bitterman, PB, Corley, RA, Ding, BS, Engler, AJ, Hansen, KC, Hagood, JS, Kheradmand, F, Lin, QS, Neptune, E, Niklason, L, Ortiz, LA, Parks, WC, Tschumperlin, DJ, White, ES, Chapman, HA, Thannickal, VJ. . Extracellular matrix in lung development, homeostasis and disease. Matrix Biol 73, 77-104 (2018).
187 Hackett, T., Ose,i ET. Modeling Extracellular Matrix-Cell Interactions in Lung Repair and Chronic Disease. Cells 10, 2145 (2021).
188 Phogat, S., Thiam, F, Al Yazeedi, S, Abokor, FA, Osei, ET. 3D in vitro hydrogel models to study the human lung extracellular matrix and fibroblast function. Respir Res 24, 242 (2023).
189 Ma, H., Wu, X, Li ,Y, Xia, Y. . Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis. Front Pharmacol 13, 963054 (2022).
190 Patel, D., Snelgrove, RJ. The multifaceted roles of the matrikine Pro-Gly-Pro in pulmonary health and disease. Eur Respir Rev 27, 180017 (2018).
191 Burgess, J., Weckmann, M. Matrikines and the lungs. Pharmacol Ther 134, 317-337 (2012).
192 Gressett , T., Hossen, ML, Talkington, G, Volic, M, Perez, H, Tiwari, PB, Chapagain, P, Bix, G. Molecular interactions between perlecan LG3 and the SARS-CoV-2 spike protein receptor binding domain. Protein Sci 33, e4843 (2024).
193 Lavorgna, T., Gressett, TE, Chastain, WH, Bix, GJ. . Perlecan: a review of its role in neurologic and musculoskeletal disease. Front Physiol 14, 1189731 (2023).
194 Hayes, A., Farrugia, BL, Biose, IJ, Bix, GJ, Melrose, J. Perlecan, A Multi-Functional, Cell-Instructive, Matrix-Stabilizing Proteoglycan With Roles in Tissue Development Has Relevance to Connective Tissue Repair and Regeneration. Front Cell Dev Biol 10, 856261 (2022).
195 Kunnathattil, M., Rahul, P, Skaria, T. Soluble vascular endothelial glycocalyx proteoglycans as potential therapeutic targets in inflammatory diseases. . Immunol Cell Biol 102, 97-116 (2024).
196 Yoshida, H., Nagaoka, A, Kusaka-Kikushima, A, Tobiishi, M, Kawabata, K, Sayo, T, Sakai, S, Sugiyama, Y, Enomoto, H, Okada, Y, Inoue, S. KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization. Proc Natl Acad Sci U S A 110, 5612-5617 (2013).
197 Shimizu, H., Shimoda, M, Mochizuki, S, Miyamae, Y, Abe, H, Chijiiwa, M, Yoshida, H, Shiozawa, J, Ishijima, M, Kaneko, K, Kanaji, A, Nakamura, M, Toyama, Y, Okada, Y. Hyaluronan-Binding Protein Involved in Hyaluronan Depolymerization Is Up-Regulated and Involved in Hyaluronan Degradation in Human Osteoarthritic Cartilage. Am J Pathol 188, 2109-2119 (2018).
198 Song, Y., He, P, Rodrigues, AL, Datta, P, Tandon, R, Bates, JT, Bierdeman, MA, Chen, C, Dordick, J, Zhang, F, Linhardt, RJ. . Anti-SARS-CoV-2 Activity of Rhamnan Sulfate from Monostroma nitidum. Mar Drugs 19, 685 (2021).
199 Koumpa, F., Forde, CT, Manjaly, JG. Sudden irreversible hearing loss post COVID-19. BMJ Case Rep 13, e238419 (2020).
200 Francis, D., Hutadilok, N, Kongtawelert, P, Ghosh, P. Pentosan polysulphate and glycosaminoglycan polysulphate stimulate the synthesis of hyaluronan in vivo. Rheumatol Int 13, 61-64 (1993).
201 Shen, B., Shimmon, S, Smith, MM, Ghosh, P. Biosensor analysis of the molecular interactions of pentosan polysulfate and of sulfated glycosaminoglycans with immobilized elastase, hyaluronidase and lysozyme using surface plasmon resonance (SPR) technology. J Pharm Biomed Anal 31, 83-93. doi: 10.1016/s0731-7085(1002)00606-00604. (2003).
202 Slevin, M., Krupinski, J, Gaffney, J, Matou, S, West ,D, Delisser, H, Savani, RC, Kumar, S. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol 26, 58-68 (2007).
203 Genasetti, A., Vigetti, D, Viola, M, Karousou, E, Moretto, P, Rizzi, M, Bartolini, B, Clerici,M, Pallotti, F, De Luca, G, Passi, A. Hyaluronan and human endothelial cell behavior. Connect Tissue Res 49, 120-123 (2008).
204 Matou-Nasri, S., Gaffney, J, Kumar, S, Slevin, M. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin. Int J Oncol 35, 761-773 (2009).
205 Slevin, M., Krupinski, J, Kumar, S, Gaffney, J. Angiogenic oligosaccharides of hyaluronan induce protein tyrosine kinase activity in endothelial cells and activate a cytoplasmic signal transduction pathway resulting in proliferation. Lab Invest 78, 987-1003 (1998).
206 Wang, Y., Cao, ML, Liu, YW, He, YQ, Yang, CX, Gao, F. CD44 mediates oligosaccharides of hyaluronan-induced proliferation, tube formation and signal transduction in endothelial cells. Exp Biol Med (Maywood) 236, 84-90 (2011).
207 Castor, C., Fremuth, TD, Furlong, AM, Jourdian, GW. Hyaluronic acid and proteoglycan synthesis by lung fibroblasts in basal and activated states. In Vitro 19, 462-470 (1983).
208 Ambrosino, P., Calcaterra, IL, Mosella, M, Formisano, R, D'Anna, SE, Bachetti, T, Marcuccio, G, Galloway, B, Mancini, FP, Papa, A, Motta, A, Di Minno, MND, Maniscalco, M. Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target. Biomedicines 10, 812 (2022).
209 Liu, N., Long, H, Sun, J, Li, H, He, Y, Wang, Q, Pan, K, Tong, Y, Wang, B, Wu, Q, Gong, L. New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression. J Med Virol 94, 3112-3120 (2022).
210 Robles, J., Zamora, M, Adan-Castro, E, Siqueiros-Marquez, L, Martinez de la Escalera, G, Clapp, C. The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB signaling. J Biol Chem 298, 101695 (2022).
211 Sbirkov, Y., Dzharov, V, Todorova, K, Hayrabedyan, S, Sarafian, V. Endothelial inflammation and dysfunction in COVID-19. Vasa 51, 62-70. doi: 10.1024/0301-1526/a000991. (2022).
212 Smith, M., Melrose, J. Xylan Prebiotics and the Gut Microbiome Promote Health and Wellbeing: Potential Novel Roles for Pentosan Polysulfate. Pharmaceuticals (Basel) 15, 1151 (2022).
213 Al-Zahrani, A., Gajewski, JB. Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome. Can Urol Assoc J 5, 113-118 (2011).
214 Anderson, J., Edelman, J, Ghosh, P. Effects of pentosan polysulphate on peripheral blood leukocyte populations and mononuclear cell procoagulant activity in patients with osteoarthritis. Curr Therap Res 58, 93-107 (1997).
215 Nickel, J., Forrest, JB, Tomera, K, Hernandez-Graulau, J, Moon, TD, Schaeffer, AJ, Krieger, JN, Zeitlin, SI, Evans, RJ, Lama, DJ, Neal, DE Jr, Sant, GR. . Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. J Urol 173, 1252-1255 (2005).
216 Nickel, J., Barkin, J, Forrest ,J, Mosbaugh, PG, Hernandez-Graulau, J, Kaufman, D, Lloyd, K, Evans, RJ, Parsons, CL, Atkinson, LE; Elmiron Study Group. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 65, 654-658 (2005).
217 Nickel, J., Herschorn, S, Whitmore, KE, Forrest, JB, Hu, P, Friedman, AJ, Baseman, AS. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol 193, 857-862 (2015).
218 Senthil, D., Malini, MM, Varalakshmi, P. Sodium pentosan polysulphate--a novel inhibitor of urinary risk factors and enzymes in experimental urolithiatic rats.. Ren Fail 20, 573-580 (1998).
219 Wallius, B., Tidholm, AE. . Use of pentosan polysulphate in cats with idiopathic, non-obstructive lower urinary tract disease: a double-blind, randomised, placebo-controlled trial. J Feline Med Surg 11, 409-412 (2009).
220 Baggen, J., Vanstreels, E, Jansen, S, Daelemans, D. . Cellular host factors for SARS-CoV-2 infection. Nat Microbiol 6, 1219-1232 (2021).
221 Takizawa, M., Ohuchi, E, Yamanaka ,H, Nakamura, H, Ikeda, E, Ghosh, P, Okada, Y. Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. Arthritis Rheum 43, 812-820 (2000).
222 Takizawa, M., Yatabe, T, Okada, A, Chijiiwa, M, Mochizuk,i S, Ghosh, P, Okada, Y. Calcium pentosan polysulfate directly inhibits enzymatic activity of ADAMTS4 (aggrecanase-1) in osteoarthritic chondrocytes. FEBS Lett 582, 2945-2949 (2008).
223 Troeberg, L., Fushimi, K, Khokha, R, Emonard, H, Ghosh, P, Nagase, H. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J 22, 3515-3524 (2008).
224 Bwalya, E., Kim, S, Fang, J, Wijekoon, HMS, Hosoya, K, Okumura, M. Pentosan polysulfate inhibits IL-1β-induced iNOS, c-Jun and HIF-1α upregulation in canine articular chondrocytes. PLoS One 12, e0177144 (2017).
225 Daly, C., Ghosh, P, Zannettino, ACW, Badal, T, Shimmon, R, Jenkin, G, Oehme, D, Jain, K, Sher, I, Vais, A, Cohen, C, Chandra, RV, Goldschlager, T. Mesenchymal progenitor cells primed with pentosan polysulfate promote lumbar intervertebral disc regeneration in an ovine model of microdiscectomy. . Spine J 18, 491-506 (2018).
226 Kumagai, K., Shirabe, S, Miyata, N, Murata, M, Yamauchi, A, Kataoka, Y, Niwa, M. Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis--an open clinical trial. . BMC Clin Pharmacol 10, 7 (2010).
227 Oehme, D., Ghosh, P, Goldschlager, T, Itescu, S, Shimon, S, Wu, J, McDonald, C, Troupis, JM, Rosenfeld, JV, Jenkin, G. Reconstitution of degenerated ovine lumbar discs by STRO-3-positive allogeneic mesenchymal precursor cells combined with pentosan polysulfate. J Neurosurg Spine 24, 715-726 (2016).
228 Andrews, J., Ghosh, P, Lentini, A, Ternai, B. . The interaction of pentosan polysulphate (SP54) with human neutrophil elastase and connective tissue matrix components. Chem Biol Interact 47, 157-173 (1983).
229 Suranji Wijekoon, H., Kim, S, Bwalya, EC, Fang, J, Aoshima, K, Hosoya, K, Okumura, M. Anti-arthritic effect of pentosan polysulfate in rats with collagen-induced arthritis. Res Vet Sci 122, 179-185 (2019).
230 Frith, J., Cameron, AR, Menzies, DJ, Ghosh, P, Whitehead, DL, Gronthos, S, Zannettino, AC, Cooper-White, JJ. An injectable hydrogel incorporating mesenchymal precursor cells and pentosan polysulphate for intervertebral disc regeneration. Biomaterials 34, 9430-9440 (2013).
231 Frith, J., Menzies, DJ, Cameron, AR, Ghosh, P, Whitehead, DL, Gronthos, S, Zannettino, AC, Cooper-White, JJ. Effects of bound versus soluble pentosan polysulphate in PEG/HA-based hydrogels tailored for intervertebral disc regeneration. Biomaterials 35, 1150-1162 (2014).
232 Lohmann, N., Schirmer, L, Atallah, P, Wandel, E, Ferrer,RA, Werner, C, Simon, JC, Franz, S, Freudenberg, U. Glycosaminoglycan-based hydrogels capture inflammatory chemokines and rescue defective wound healing in mice. Sci Transl Med 9, pii: eaai9044 (2017).
233 Kilgore, K., Naylor, KB, Tanhehco, EJ, Park, JL, Booth, EA, Washington, RA, Lucchesi, BR. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart. J Pharmacol Exp Ther 285, 987-994 (1998).
234 Klegeris, A., Singh, EA, McGeer, PL. . Effects of C-reactive protein and pentosan polysulphate on human complement activation. Immunology 106, 381-388 (2002).
235 Fischer, A., Barrowcliffe, TW, Thomas, DP. . A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation. Thromb Haemost 47, 104-108 (1982).
236 Giedrojć, J., Radziwon, P, Klimiuk, M, Bielawiec, M, Breddin, HK, Kłoczko, J. Experimental studies on the anticoagulant and antithrombotic effects of sodium and calcium pentosan polysulphate. J Physiol Pharmacol 50, 111-119 (1999).
237 Orme, C., Harris, RC. . A comparison of the lipolytic and anticoagulative properties of heparin and pentosan polysulphate in the thoroughbred horse. Acta Physiol Scand 59, 179-185 (1997).
238 Vinazzer, H. Effect of pentosan polysulfate on fibrinolysis: basic tests and clinical application. Semin Thromb Hemost 17, 375-378 (1991).
239 Goad, K., Horne, MK 3rd, Gralnick, HR. Pentosan-induced thrombocytopenia: support for an immune complex mechanism. Br J Haematol 88, 803-808 (1994).
240 Tardy-Poncet, B., Tardy, B, Grelac, F, Reynaud, J, Mismetti, P, Bertrand, JC, Guyotat, D. Pentosan polysulfate-induced thrombocytopenia and thrombosis. Am J Hematol 45, 252-257 (1994).
241 Verbruggen, G., Veys, EM. Intra-articular injection pentosan polysulphate results in increased hyaluronan molecular weight in joint fluid. Clin Exp Rheumatol 10, 249-254 (1992).
242 Stapledon, C., Tsangari, H, Solomon, LB, Campbell, DG, Hurtado, P, Krishnan, R, Atkins, GJ. Human osteocyte expression of Nerve Growth Factor: The effect of Pentosan Polysulphate Sodium (PPS) and implications for pain associated with knee osteoarthritis. PLoS One 14, e0222602 (2019).
243 Sampson, M., Kabbani, M, Krishnan, R, Nganga, M, Theodoulou, A, Krishnan, J. Improved clinical outcome measures of knee pain and function with concurrent resolution of subchondral Bone Marrow Edema Lesion and joint effusion in an osteoarthritic patient following Pentosan Polysulphate Sodium treatment: a case report. BMC Musculoskelet Disord 18, 396 (2017).
244 Pluda, J., Shay, LE, Foli, A, Tannenbaum, S, Cohen, PJ, Goldspiel, BR, Adamo, D, Cooper, MR, Broder, S, Yarchoan, R. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 85, 1585-1592 (1993).
245 Alberca, G., Solis-Castro, RL, Solis-Castro, ME, Alberca, RW. . Coronavirus disease-2019 and the intestinal tract: An overview. World J Gastroenterol 27, 1255-1266, doi:doi: 10.3748/wjg.v27.i13.1255. (2021).
246 He, F., Zhang, T, Xue, K, Fang, Z, Jiang, G, Huang, S, Li, K, Gu, Z, Shi, H, Zhang, Z, Zhu, H, Lin, L, Li, J, Xiao, F, Shan, H, Yan, R, Li, X, Yan, Z. . Fecal multi-omics analysis reveals diverse molecular alterations of gut ecosystem in COVID-19 patients. Anal Chim Acta 1180, 338881, doi:doi: 10.1016 /j.aca.2021.338881 (2021).
247 Zhang, B., Zhong, Y, Dong, D, Zheng, Z, Hu, J. Gut microbial utilization of xylan and its implication in gut homeostasis and metabolic response. Carbohydr Polym 286, 119271 (2022).
248 Lee JY, T. R., Bäumler AJ. The microbiome and gut homeostasis. Science 377, eabp9960 (2022).
249 Xiao, Z., Pan, M, Li, X, Zhao, C. Impact of SARS-CoV2 infection on gut microbiota dysbiosis. Microbiome Res Rep 3, 7 (2023).
250 Nordberg Karlsson, E., Schmitz, E, Linares-Pastén, JA, Adlercreutz, P. Endo-xylanases as tools for production of substituted xylooligosaccharides with prebiotic properties. Appl Microbiol Biotechnol 102, 9081-9088 (2018).
251 Zhang, M., Chekan, JR, Dodd, D, Hong, PY, Radlinski, L, Revindran, V, Nair, SK, Mackie, RI, Cann, I. Xylan utilization in human gut commensal bacteria is orchestrated by unique modular organization of polysaccharide-degrading enzymes. Proc Natl Acad Sci U S A. 111, E3708-3717 (2014).
252 Childs, C., Röytiö, H, Alhoniemi, E, Fekete, AA, Forssten, SD, Hudjec, N, Lim, YN, Steger ,CJ, Yaqoob, P, Tuohy, KM, Rastall, RA, Ouwehand, AC, Gibson, GR. Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalis subsp. lactis induce bifidogenesis and modulate markers of immune function in healthy adults: a double-blind, placebo-controlled, randomised, factorial cross-over study. Br J Nutr 111, 1945-1956 (2014).
253 Gesaka, S., Obimbo, MM, Wanyoro, A. . Coronavirus disease 2019 and the placenta: A literature review. Placenta 126, 209-223 (2022).
254 Ojha, R., Gurjar, K, Ratnakar, TS, Mishra, A, Prajapati, VK. . Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. Hum Immunol 83, 346-355 (2022).
255 Chaves-Medina, M., Gómez-Ospina, JC, García-Perdomo, HA. . Molecular mechanisms for understanding the association between TMPRSS2 and beta coronaviruses SARS-CoV-2, SARS-CoV and MERS-CoV infection: scoping review. Arch Microbiol 204, 77 (2021).
256 Jacobs, J., Booth, GS. COVID-19 and Immune-Mediated RBC Destruction. Am J Clin Pathol 157, 844-851 (2022).
257 Wendisch, D., Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, Chua RL, Knoll R, Timm S, Brumhard S, Krammer T, Zauber H, Hiller AL, Pascual-Reguant A, Mothes R, Bülow RD, Schulze J, Leipold AM, Djudjaj S, Erhard F, Geffers R, Pott F, Kazmierski J, Radke J, Pergantis P, Baßler K, Conrad C, Aschenbrenner AC, Sawitzki B, Landthaler M, Wyler E, Horst D; Deutsche COVID-19 OMICS Initiative (DeCOI), Hippenstiel S, Hocke A, Heppner FL, Uhrig A, Garcia C, Machleidt F, Herold S, Elezkurtaj S, Thibeault C, Witzenrath M, Cochain C, Suttorp N, Drosten C, Goffinet C, Kurth F, Schultze JL, Radbruch H, Ochs M, Eils R, Müller-Redetzky H, Hauser AE, Luecken MD, Theis FJ, Conrad C, Wolff T, Boor P, Selbach M, Saliba AE, Sander LE. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell 184, 6243-6261.e6227 (2021).
258 Acharya, Y., Alameer, A, Calpin, G, Alkhattab, M, Sultan, S. . A comprehensive review of vascular complications in COVID-19. J Thromb Thrombolysis 53, 586-593 (2022).
259 Veizades, S., Tso, A, Nguyen, PK. . Infection, inflammation and thrombosis: a review of potential mechanisms mediating arterial thrombosis associated with influenza and severe acute respiratory syndrome coronavirus 2. Biol Chem 403, 231-241 (2021).
260 Plášek, J., Gumulec, J, Máca, J, Škarda, J, Procházka, V, Grézl, T, Václavík, J. COVID-19 associated coagulopathy: Mechanisms and host-directed treatment. Am J Med Sci 363, 465-475 (2022).
261 Rizal, S., Joshi, BR, Regmi, S. . Raised D-dimer Level among COVID-19 Patients in a Tertiary Care Hospital: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc 60, 259-262 (2022).
262 Al-Kuraishy, H., Al-Gareeb, AI, Kaushik, A, Kujawska, M, Batiha, GE. Hemolytic anemia in COVID-19. Ann Hematol 101, 1887-1895 (2022).
263 Wagener, F., Pickkers,, P, Peterson SJ, Immenschuh, S, Abraham, NG. Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections.. Antioxidants (Basel) 9, 540 (2020).
264 Ousaka, D., Nishibori, M. Is hemolysis a novel therapeutic target in COVID-19? Front Immunol 13, 956671 (2022).
265 Natale, N., Lukens, JR, Petri, WA Jr. The nervous system during COVID-19: Caught in the crossfire. Immunol Rev doi: 10.1111/imr.13114. (2022).
266 Valdes, E., Fuchs, B, Morrison, C, Charvet, L, Lewis, A, Thawani, S, Balcer, L, Galetta, SL, Wisniewski, T, Frontera, JA. Demographic and social determinants of cognitive dysfunction following hospitalization for COVID-19. J Neurol Sci 438, 120146 (2022).
267 Meyer , P., Hellwig, S, Blazhenets, G, Hosp, JA. Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review. J Nucl Med 63, 971-980 (2022).
268 Kao, J., Frankland, PW. COVID fog demystified. Cell S0092-8674, 00725-00725 (2022).
269 Maltezou, H., Pavli, A, Tsakris, A. . Post-COVID Syndrome: An Insight on Its Pathogenesis. Vaccines (Basel) 9, 497 (2021).
270 García-Grimshaw, M., Sankowski, R, Valdés-Ferrer, SI. . Neurocognitive and psychiatric post-coronavirus disease 2019 conditions: pathogenic insights of brain dysfunction following severe acute respiratory syndrome coronavirus 2 infection. Curr Opin Neurol 35, 375-383 (2022).
271 Anonymous. Long COVID and kids: more research is urgently needed. Nature 602, 183 (2022).
272 Ortona, E., Malorni, W. Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy. Eur Respir J 59, 2102245 (2022).
273 Schober, M., Robertson, CL, Wainwright, MS, Roa, JD, Fink, EL. COVID-19 and the Pediatric Nervous System: Global Collaboration to Meet a Global Need. Neurocrit Care 35, 283-290 (2021).
274 Deoni, S., Beauchemin, J, Volpe, A, Dâ Sa, V; RESONANCE Consortium. Impact of the COVID-19 Pandemic on Early Child Cognitive Development: Initial Findings in a Longitudinal Observational Study of Child Health. medRxiv [Preprint]. 08.10.21261846 (2021).
275 Dyer, O. Covid-19: Children born during the pandemic score lower on cognitive tests, study finds. BMJ. 2021 Aug 16;374:n2031. Dyer O. Covid-19: Children born during the pandemic score lower on cognitive tests, study finds. BMJ 374, n2031 (2021).
276 Ehrler, M., Werninger, I, Schnider, B, Eichelberger, DA, Naef,N, Disselhoff, V, Kretschmar, O, Hagmann, CF, Latal ,B, Wehrle, FM. Impact of the COVID-19 pandemic on children with and without risk for neurodevelopmental impairments. Acta Paediatr. 110, 1281-1288 (2021).
277 Liu, K., Howard, R, Banerjee, S, Comas-Herrera, A, Goddard, J, Knapp, M, Livingston, G, Manthorpe, J, O'Brien, JT, Paterson, RW, Robinson, L, Rossor, M, Rowe, JB, Sharp, DJ, Sommerlad, A, Suárez-González, A, Burns, A. Dementia wellbeing and COVID-19: Review and expert consensus on current research and knowledge gaps. Int J Geriatr Psychiatry 36, 1597-1639 (2021).
278 Hampshire, A., Trender, W, Chamberlain, SR, Jolly, AE, Grant, JE, Patrick, F, Mazibuko, N, Williams, SC, Barnby, JM, Hellyer, P, Mehta, MA. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine 39, 101044 (2021).
279 Palakshappa, J., Krall, JTW, Belfield, LT, Files, DC. Long-Term Outcomes in Acute Respiratory Distress Syndrome: Epidemiology, Mechanisms, and Patient Evaluation. Crit Care Clin 37, 895-911 (2021).
280 Schou, T., Joca, S, Wegener, G, Bay-Richter, C. Psychiatric and neuropsychiatric sequelae of COVID-19 - A systematic review. Brain Behav Immun 97, 328-348 (2021).
281 Yang, F., Zhao, H, Liu, H, Wu, X, Li, Y. . Manifestations and mechanisms of central nervous system damage caused by SARS-CoV-2. Brain Res Bull S0361-9230, 00284-00287 (2021).
282 Yong, S. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 53, 737-754 (2021).
283 Aiyegbusi, O., Hughes, SE, Turner, G, Rivera, SC, McMullan, C, Chandan, JS, Haroon, S, Price, G, Davies, EH, Nirantharakumar, K, Sapey, E, Calvert, MJ; TLC Study Group. Symptoms, complications and management of long COVID: a review. J R Soc Med 114, 428-442 (2021) (2021).
284 Chen, J., Zhang, W, Li, Y, Liu, C, Dong, T, Chen, H, et al Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor. Cell 188, 1729-1742.e1716. doi: 1710.10 16/j.cell.2025.1701.1042. (2025).
285 Srivastava, S., Sharma, D, Sridhar, SB, Kumar, S, Sahu, R, Ashique, S, et al HKU5-CoV-2: A silent threat looming in bats. Travel Med Infect Dis 65, 102838. doi: 102810.101016/j.tmaid.102025.102838. (2025).
286 Wang, N., Ji, W, Jiao, H, Veit ,M, Sun, J, Wang, Y, et al A MERS-CoV-like mink coronavirus uses ACE2 as an entry receptor. Nature 642, 739-746. doi: 710.1038/s41586-41025-09007-w. (2025).
2 Yisimayi, A., et al., Repeated Omicron exposures override ancestral SARSCoV-2 immune imprinting. Nature 625, 148-156 (2024).
3 Cele, S., et al., Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654-656 (2022).
4 Kaku, Y., et al., Virological characteristics of the SARS-CoV-2 KP.2 variant. Lancet Infect Dis (2024).
5 Plante, J. A., et al., Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116-121 (2021).
6 Lopes-Pacheco, M., Silva, PL, Cruz, FF, Battaglini, D, Robba, C, Pelosi, P, Morales, MM, Caruso Neves, C, Rocco, PRM. Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. Front Physiol 12, 593223 (2021).
7 Mokhtari, T., Hassani, F, Ghaffari, N, Ebrahimi, B, Yarahmadi, A, Hassanzadeh, G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. J Mol Histol 51, 613-628 (2020).
8 Zaim, S., Chong, JH, Sankaranarayanan, V, Harky, A. COVID-19 and Multiorgan Response. Curr Probl Cardiol 45, 100618 (2020).
9 Narayanan, S., Jamison, DA, Guarnieri, JW et al. A comprehensive SARS-CoV-2 and COVID-19 review, Part 2: host extracellular to systemic effects of SARS-CoV-2 infection. Eur J Hum Genet 32, 10-20 (2024).
10 Tang, D., Comish ,P, Kang, R The hallmarks of COVID-19 disease. PLoS Pathog 16, e1008536 (2020).
11 Menon, N., Mohapatra, S. The COVID-19 pandemic: Virus transmission and risk assessment. Curr Opin Environ Sci Health 28, 100373 (2022).
12 Smith, M., Melrose, J. Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues. . Pharmaceuticals (Basel) 16, 437 (2023).
13 Smith, M., Hayes, AJ, Melrose, J. Pentosan Polysulfate, a Semisynthetic Heparinoid Disease-Modifying Osteoarthritic Drug with Roles in Intervertebral Disc Repair Biology Emulating the Stem Cell Instructive and Tissue Reparative Properties of Heparan Sulfate. Stem Cells Dev 31, 406-430. doi: 410.1089/scd.2022.0007 (2022).
14 Fehr, A., Perlman, S. Coronaviruses: an overview of their replication and pathogenesis. Methoda Mol Biol 1282, 1-23 (2015).
15 Rabaan, A., Al-Ahmed,SH, Haque, S, Sah, R, Tiwari, R, Malik, YS, Dhama, K, Yatoo, MI, Bonilla-Aldana, DK, Rodriguez-Morales, AJ. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med 28, 174-184 (2020).
16 Rabaan, A., Al-Ahmed,SH, Haque, S, Sah, R, Tiwari, R, Malik, YS, Dhama, K, Yatoo, MI, Bonilla-Aldana, DK, Rodriguez-Morales, AJ. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med 28, 174-184 (2020).
17 Chafekar, A., Fielding, BC. MERS-CoV: understanding the latest human coronavirus threat. Viruses 10, 93 (2018).
18 Worldometer. Coronavirus death toll. https://http://www.worldometers.info/coronavirus/coronavirus-death-toll/ (2022).
19 Bhat, E., Khan, J, Sajjad, N, Ali, A, Aldakeel, FM, Mateen, A, Alqahtani, MS, Syed, R. SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis - An updated review. Int Immunopharmacol 95, 107493 (2021).
20 Guney, C., Akar, F. Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes. J Pharm Pharm Sci 24, 84-93 (2021).
21 Kim, S., Jin, W, Sood, A, Montgomery, DW, Grant, OC, Fuster, MM, Fu, L, Dordick, JS, Woods, RJ, Zhang, F, Linhardt, RJ. . Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res 181, 104873 (2020).
22 Rusnati, M., Urbinati, C, Caputo, A, Possati,L, Lortat-Jacob, H, Giacca, M, Ribatti, D, Presta, M. . Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem 276, 22420-22425 (2001).
23 Tandon, R., Sharp, JS, Zhang, F, Pomin, VH, Ashpole, NM, Mitra, D, McCandless, MG, Jin, W, Liu, H, Sharma, P, Linhardt, RJ. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. J Virol 95, e01987-01920 (2021).
24 Yu, M., Zhang, T, Zhang, W, Sun, Q, Li,H, Li, JP. Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins-An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic. Front Mol Biosci 7, 628551 (2021).
25 Schuurs, Z., Hammond, E, Elli, S, Rudd, TR, Mycroft-West, CJ, Lima, MA, Skidmore, MA, Karlsson, R, Chen, YH, Bagdonaite, I, Yang, Z, Ahmed, YA, Richard, DJ, Turnbull, J, Ferro, V, Coombe, DR, Gandhi, NS. . Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. Comput Struct Biotechnol J 19, 2806-2818 (2021).
26 Clausen, T., Sandoval, DR, Spliid, CB, Pihl, J, Painter, CD, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183, 1043-1057 (2020).
27 Partridge, L., Urwin, L, Nicklin, MJH, James, DC, Green, LR, Monk, PN. ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin. Cells 10, 1419 (2021).
28 Nie, C., Pouyan, P, Lauster, D, Trimpert, J, Kerkhoff, Y, Szekeres, GP, Wallert, M, Block, S, Sahoo, AK, Dernedde, J, Pagel,K, Kaufer, BB, Netz, RR, Ballauff, M, Haag, R. Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions*. Angew Chem Int Ed Engl 60, 15870-15878 (2021).
29 Kearns, F., Sandoval, DR, Casalino, L, Clausen, TM, Rosenfeld, MA, Spliid, CB, Amaro, RE, Esko, JD. Spike-heparan sulfate interactions in SARS-CoV-2 infection. Curr Opin Struct Biol 76, 102439 (2022).
30 Bhat, E., Khan, J, Sajjad, N, Ali, A, Aldakeel, FM, Mateen, A, Alqahtani, MS, Syed, R. SARS-CoV-2: Insight in genome structure, pathogenesis and viral receptor binding analysis - An updated review. Int Immunopharmacol 95, 107493 (2021).
31 Guney, C., Akar, F. Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes. J Pharm Pharm Sci 24, 84-93 (2021).
32 Rusnati, M., Urbinati, C, Caputo, A, Possati,L, Lortat-Jacob, H, Giacca, M, Ribatti, D, Presta, M. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem 276, 22420-22425 (2001).
33 Tandon, R., Sharp, JS, Zhang, F, Pomin, VH, Ashpole, NM, Mitra, D, McCandless, MG, Jin, W, Liu, H, Sharma, P, Linhardt, RJ. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. J Virol 95, e01987-01920 (2021).
34 Yadav, R., Chaudhary, JK, Jain, N, Chaudhary, PK, Khanra, S, Dhamija, P, Sharma, A, Kumar, A, Handu, S. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells 10, 821 (2021).
35 Yuan, H., Wen,HL. Research progress on coronavirus S proteins and their receptors. . Arch Virol 28 (2021).
36 Mahmoud, I., Jarrar, YB. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges. Mol Biol Rep doi: 10.1007/s11033-021-06390-1 (2021).
37 Cantuti-Castelvetri, L., Ojha, R, Pedro, LD, Djannatian, M, Franz, J, Kuivanen, S, van der Meer, F, Kallio, K, Kaya, T, Anastasina, M, Smura, T, Levanov, L, Szirovicza, L, Tobi, A, Kallio-Kokko, H, Österlund, P, Joensuu, M, Meunier, FA, Butcher, SJ, Winkler, MS, Mollenhauer, B, Helenius, A, Gokce, O, Teesalu, T, Hepojoki, J, Vapalahti, O, Stadelmann, C, Balistreri, G, Simons, M. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370, 856-860 (2020).
38 Chekol Abebe, E., Mengie Ayele, T, Tilahun Muche, Z, Asmamaw Dejenie, T. . Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target. Biologics 15, 143-152 (2021).
39 Daly, J., Simonetti, B, Klein, K, Chen, KE, Williamson, MK, Antón-Plágaro, C, Shoemark, DK, Simón-Gracia, L, Bauer, M, Hollandi, R, Greber, UF, Horvath, P, Sessions, RB, Helenius, A, Hiscox, JA, Teesalu, T, Matthews, DA, Davidson, AD, Collins, BM, Cullen, PJ, Yamauchi, Y. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science 370, 861-865 (2020).
40 Sajuthi, S., DeFord, P, Li, Y, Jackson, ND, Montgomery, MT, Everman, JL, Rios, CL, Pruesse, E, Nolin, JD, Plender, EG, Wechsler, ME, Mak, ACY, Eng, C, Salazar, S, Medina, V, Wohlford, EM, Huntsman, S, Nickerson, DA, Germer, S, Zody, MC, Abecasis, G, Kang, HM, Rice, KM, Kumar, R, Oh, S, Rodriguez-Santana, J, Burchard, EG, Seibold, MA. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. . Nat Commun 11, 5139 (2020).
41 Zmora, P., Moldenhauer, AS, Hofmann-Winkler, H, Pöhlmann, S. TMPRSS2 Isoform 1 Activates Respiratory Viruses and Is Expressed in Viral Target Cells. . PLoS One 10, e0138380 (2015).
42 Bertram, S., Glowacka, I, Steffen, I, Kühl, A, Pöhlmann, S Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev Med Virol 20, 298-310 (2010).
43 Bertram, S., Glowacka, I, Blazejewska, P, Soilleux, E, Allen, P, Danisch, S, et al. . . TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. . J Virol 84, 10016-10025 (2010).
44 Muralidar, S., Gopal, G, Visaga, Ambi, S. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19. J Med Virol doi: 10.1002/jmv.27019 (2021).
45 Davies, J., Randeva, HS, Chatha, K, Hall, M, Spandidos, DA, Karteris, E, Kyrou, I. . Neuropilin 1 as a new potential SARS CoV 2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID 19. Mol Med Rep 22, 4221-4226 (2020).
46 Berrou, E., Quarck, R, Fontenay-Roupie, M, Lévy-Toledano, S, Tobelem, G, Bryckaert, M. Transforming growth factor-beta 1 increases internalization of basic fibroblast growth factor by smooth muscle cells: implication of cell-surface heparan sulphate proteoglycan endocytosis. Biochem J 311, 393-399 (1995).
47 Christianson, H., Belting, M. . Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biol 35, 51-55 (2014).
48 Neill, T., Schaefer, L, Iozzo, RV. Decoding the Matrix: Instructive Roles of Proteoglycan Receptors. Biochemistry 54, 4583-4598 (2015).
49 Balistreri, G., Yamauchi, Y, Teesalu, T. A widespread viral entry mechanism: The C-end Rule motif-neuropilin receptor interaction. Proc Natl Acad Sci USA 118, e2112457118 (2021).
50 Danthi, P., Holm, GH, Stehle, T, Dermody, TS. Reovirus receptors, cell entry, and proapoptotic signaling. Adv Exp Med Biol 790, 42-71 (2013).
51 Inoue, J., Ninomiya, M, Shimosegawa, T, McNiven, MA. Cellular Membrane Trafficking Machineries Used by the Hepatitis Viruses. Hepatology 68, 751-762 (2018).
52 Mikuličić, S., Florin, L. The endocytic trafficking pathway of oncogenic papillomaviruses. Papillomavirus Res 7, 135-137 (2019).
53 Perera-Lecoin, M., Meertens, L, Carnec, X, Amara, A. Flavivirus entry receptors: an update. Viruses 6, 69-88 (2013).
54 Altgärde, N., Eriksson, C, Peerboom, N, Block, S, Altgärde, N, Wahlsten, O, Möller, S, Schnabelrauch, M, Trybala, E, Bergström, T, Bally, M. Binding Kinetics and Lateral Mobility of HSV-1 on End-Grafted Sulfated Glycosaminoglycans. Biophys J 113, 1223-1234 (2017).
55 Egedal, J., Xie, G, Packard, TA, Laustsen, A, Neidleman, J, Georgiou, K, Pillai, SK, Greene, WC, Jakobsen, MR, Roan, NR. . Hyaluronic acid is a negative regulator of mucosal fibroblast-mediated enhancement of HIV infection. Mucosal Immunol 14, 1203-1213 (2021).
56 Li, P., Fujimoto, K, Bourguingnon, L, Yukl, S, Deeks, S, Wong, JK. Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4(+) T cells. Immunol Cell Biol 92, 770-780 (2014).
57 Peerboom, N., Phan-Xuan, T, Moeller, S, Schnabelrauch, M, Svedhem, S, Trybala, E, Bergström, T, Bally, M. Mucin-like Region of Herpes Simplex Virus Type 1 Attachment Protein Glycoprotein C (gC) Modulates the Virus-Glycosaminoglycan Interaction. J Biol Chem 290, 21473-21485 (2015).
58 Turville, S. Blocking of HIV entry through CD44-hyaluronic acid interactions. Immunol Cell Biol 92, 735-736 (2014).
59 Smith, M., Melrose, J. Impaired instructive and protective barrier functions of the endothelial cell glycocalyx pericellular matrix is impacted in COVID-19 disease. J Cell Mol Med 28, e70033. doi: 70010.71111/jcmm.70033. (2024).
60 Libby, P., and Luscher, T. COVID-19 is, in the end, an endothelial disease. Eur Heart J 41, 3038-3044 (2020).
61 Yang, J., LeBlanc, ME, Cano, I, Saez-Torres, KL, Saint-Geniez, M, Ng, YS, et al. . ADAM10 and ADAM17 proteases mediate proinflammatory cytokine-induced and constitutive cleavage of endomucin from the endothelial surface. J Biol Chem 295, 6641-6651 (2020).
62 Baggen, J. e. a. Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nat Genet https://doi.org/10.1038/s41588-021-00805-2 (2021).
63 Liu, L., Chopra, P, Li, X, Bouwman, KM, Tompkins, SM, Wolfert, MA, de Vries, RP, Boons, GJ. Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2. ACS Cent Sci 7, 1009-1018 (2021).
64 Zhang, Q. e. a. Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov 6, 80 (2020).
65 Bao, L. e. a. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830-833 (2020).
66 Hoffmann, M. e. a. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell https://doi.org/10.1016/j.cell.2020.02.052 (2020).
67 Lan, J. e. a. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215-220 (2020).
68 Schneider, W. e. a. Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. Cell 184, 120-132 (2021).
69 Sun, S. e. a. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124-133 (2020).
70 Zhou, P. e. a. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273 (2020).
71 Balistreri, G., Yamauchi, Y, Teesalu, T. A widespread viral entry mechanism: The C-end Rule motif-neuropilin receptor interaction. . Proc Natl Acad Sci USA 118, e2112457118 (2021).
72 Cantuti-Castelvetri, L., Ojha, R, Pedro, LD, Djannatian, M, Franz, J, Kuivanen, S, van der Meer, F, Kallio, K, Kaya, T, Anastasina, M, Smura, T, Levanov, L, Szirovicza, L, Tobi, A, Kallio-Kokko, H, Österlund, P, Joensuu, M, Meunier, FA, Butcher, SJ, Winkler, MS, Mollenhauer, B, Helenius, A, Gokce, O, Teesalu, T, Hepojoki, J, Vapalahti, O, Stadelmann, C, Balistreri, G, Simons, M. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370, 856-860 (2020).
73 Shi, Q., Jiang, J, Luo, G. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J Virol 87, 6866-6875. doi: 6810.1128/JVI.03475-03412. (2013).
74 Okamoto, K., Kinoshita, H, Parquet, MDC, Raekiansyah, M, Kimura, D, Yui, K, et al Dengue virus strain DEN2 16681 utilizes a specific glycochain of syndecan-2 proteoglycan as a receptor. J Gen Virol 93, 761-770. doi: 710.1099/ vir.1090.037853-037850. (2012).
75 Tripathi, S., Li, Y, Luo, G. Syndecan 2 proteoglycan serves as a hepatitis B virus cell attachment receptor. J Virol e0079625. doi: 10.1128/jvi.00796-25 (2025).
76 de Witte, L., Bobardt, M, Chatterji, U, Degeest, G, David, G, Geijtenbeek, TB, Gallay, P. . Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci U S A 104, 19464-19469. doi: 19410.11073/pnas.0703747104. (2007).
77 Hudák, A., Roach, M, Pusztai, D, Pettkó-Szandtner, A, Letoha, A, Szilák, L, et al Syndecan-4 Mediates the Cellular Entry of Adeno-Associated Virus 9. Int J Mol Sci 24, 3141. doi: 3110.3390 /ijms24043141. (2023).
78 Wang, R., Wang, X, Ni, B, Huan, CC, Wu, JQ, Wen, LB, et al Syndecan-4, a PRRSV attachment factor, mediates PRRSV entry through its interaction with EGFR. . Biochem Biophys Res Commun 475, 230-237. doi: 210.1016/j.bbrc.2016 .1005.1084. (2016).
79 Verrier, E., Colpitts, CC, Bach, C, Heydmann, L, Weiss, A, Renaud, M, et al. . A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. Hepatology 63, 35-48. doi: 10.1002 /hep.28013. (2016).
80 Hu, S., Zhao, K, Lan, Y, Shi, J, Guan, J, Lu, H, et al Cell-surface glycans act as attachment factors for porcine hemagglutinating encephalomyelitis virus. Vet Microbiol 265, 109315. doi: 109310.1010 16/j.vetmic.102021.109315. (2022).
81 Shafti-Keramat, S., Handisurya, A, Kriehuber, E, Meneguzzi, G, Slupetzky, K, Kirnbauer, R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77, 13125-13135. doi: 13110.11128/jvi.13177 .13124.13125-13135.12003 (2003).
82 Shafti-Keramat, S., Handisurya, A, Kriehuber, E, Meneguzzi, G, Slupetzky, K, Kirnbauer, R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77, 13125-13135. doi: 13110.11128/jvi.13177 .13124.13125-13135.12003. (2003).
83 Bermejo-Jambrina, M., Eder, J, Kaptein, TM, van Hamme, JL, Helgers, LC, Vlaming, KE, et al Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. . EMBO J 40, e106765. doi: 106710.115252/embj.2020106765 (2021).
84 Gallay, P. Syndecans and HIV-1 pathogenesis. Microbes Infect 6, 617-622. doi: 610.1016/j.micinf .2004.1002.1004. (2004).
85 Bobardt , M., Saphire, AC, Hung, HC, Yu, X, Van der Schueren, B, Zhang, Z, et al Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 18, 27-39. doi: 10.1016/s1 074-7613(1002)00504-00506. (2003).
86 Saphire, A., Bobardt, MD, Zhang, Z, David, G, Gallay, PA. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol 75, :9187-9200. doi: 9110.1128/JVI.9175.9119.9187-9200.2001. (2001).
87 Chhabra, M., Shanthamurthy, CD, Kumar ,NV, Mardhekar, S, Vishweshwara, SS, Wimmer, N, Modhiran, N, Watterson, D, Amarilla, AA, Cha, JS, Beckett, JR, De Voss, JJ, Kayal, Y, Vlodavsky, I, Dorsett ,LR, Smith, RAA, Gandhi, NS, Kikkeri, R, Ferro, V. Amphiphilic Heparinoids as Potent Antiviral Agents against SARS-CoV-2. J Med Chem 67, 11885-11916. doi: 11810.11021/acs.jmedche m.11884c00487. (2024).
88 De Clercq, E. Potential drugs for the treatment of AIDS. J Antimicrob Chemother 23 Suppl A, 35-46. doi: 10.1093/jac/1023.suppl_a.1035 (1989).
89 Vert, M. The non-specific antiviral activity of polysulfates to fight SARS-CoV-2, its mutants and viruses with cationic spikes. J Biomater Sci Polym Ed 32, 1466-1471. doi: 1410.1080/09205063.0920 2021.01925391. (2021).
90 Pavan, M., Fanti ,CD, Lucia, AD, Canato, E, Acquasaliente, L, Sonvico, F, Delgado, J, Hicks. A, Torrelles, JB, Kulkarni ,V, Dwivedi ,V, Zanellato, AM, Galesso, D, Pasut, G, Buttini, F, Martinez-Sobrido, L, Guarise, C. Aerosolized sulfated hyaluronan derivatives prolong the survival of K18 ACE2 mice infected with a lethal dose of SARS-CoV-2. Eur J Pharm Sci 187, 106489. doi: 106410. 101016/j.ejps.102023.106489. (2023).
91 Baba, M., Nakajima, M, Schols, D, Pauwels, R, Balzarini, J, De Clercq, E. . Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res 9, 335-343. doi: 310.1016/0166-3542(1088)90035-90036. (1988).
92 Rusnati, M., Urbinati, C, Caputo, A, Possati, L, Lortat-Jacob, H, Giacca, M, Ribatti, D, Presta, M. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem 276, 22420-22425 (2001).
93 Biesert, L., Suhartono, H, Winkler, I, Meichsner, C, Helsberg, M, Hewlett, G, Klimetzek, V, Mölling, K, Schlumberger, HD, Schrinner, E, et al. Inhibition of HIV and virus replication by polysulphated polyxylan: HOE/BAY 946, a new antiviral compound. AIDS 2, 449-457. doi: 410.109 7/00002030-198812000-198800007. (1988).
94 Biesert , L., Adamski, M, Zimmer, G, Suhartono, H, Fuchs, J, Unkelbach, U, Mehlhorn, RJ, Hideg, K, Milbradt, R, Rübsamen-Waigmann, H. . Anti-human immunodeficiency virus (HIV) drug HOE/BAY946 increases membrane hydrophobicity of human lymphocytes and specifically suppresses HIV-protein synthesis. Med Microbiol Immunol 179, 307-321. doi: 310.1007/BF00189609. (1990).
95 von Briesen, H., Meichsner ,C, Andreesen, R, Esser, R, Schrinner, E, Rübsamen-Waigmann, H. . The polysulphated polyxylan Hoe/Bay-946 inhibits HIV replication on human monocytes/macrophage s. Res Virol 141, 251-257. doi: 210.1016/0923-2516(1090)90029-i. (1990).
96 Peters, M., Witvrouw, M, De Clercq, E, Ruf, B. Pharmacokinetics of intravenous pentosan polysulphate (HOE/BAY 946) in HIV-positive patients. AIDS 5, 1534-1535. doi: 1510.1097/000 02030-199112000-199100021. (1991).
97 Pearce-Pratt, R., Phillips, DM. . Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 54, 173-182. doi: 110.1095/biolreprod 1054.1091.1173. (1996).
98 Witvrouw, M., Desmyter, J, De Clercq, E. . Antiviral portrait series: 4. Polysulfates as inhibitors of HIV and other enveloped viruses. . Antiviral Chemistry & ChemotherapY 5, 345-359 (1994).
99 Jurkiewicz E, P. P., Jentsch KD, Hartmann H, Hunsmann G. In vitro anti-HIV-1 activity of chondroitin polysulphate. AIDS. 3, 423-427. doi: 410.1097/00002030-198907000-198900003. (1989).
100 Vanderlinden, E., Boonen, A, Noppen, S, Schoofs, G, Imbrechts, M, Geukens, N, Snoeck, R, Stevaert ,A, Naesens, L, Andrei ,G, Schols, D. PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding. Antiviral Res 217, 105700. doi: 105710.101016/j.antiviral.10 2023.105700. (2023).
101 Huskens, D., Profy, AT, Vermeire, K, Schols, D. PRO 2000, a broadly active anti-HIV sulfonated compound, inhibits viral entry by multiple mechanisms. Retrovirology 7 Suppl 1, P17. doi: 10.1186/1742-4690-1187-S1181-P1117 (2010).
102 Nakamura, T., Satoh, K, Fukuda, T, Kinoshita, I, Nishiura, Y, Nagasato, K, Yamauchi, A, Kataoka, Y, Nakamura, T, Sasaki, H, Kumagai, K, Niwa, M, Noguchi, M, Nakamura, H, Nishida, N, Kawakami, A. Pentosan polysulfate treatment ameliorates motor function with increased serum soluble vascular cell adhesion molecule-1 in HTLV-1-associated neurologic disease. J Neurovirol 20, 269-277. doi: 210.1007/s13365-13014-10244-13368. (2014).
103 Callaway, E. Heavily mutated Omicron variant puts scientists on alert. Nature 600, 21 (2021).
104 WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern. (2021).
105 Smith, M., Melrose, J. . Pentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues. Pharmaceuticals (Basel). 16, 437 (2023).
106 GISAID. https://www.gisaid.org/hcov19-variants/. (2021).
107 Basheer, A., Zahoor, I, Yaqub, T. . Genomic architecture and evolutionary relationship of BA.2.75: A Centaurus subvariant of Omicron SARS-CoV-2. PLoS One 18, e0281159. doi: 0281110.0 281371/journal.pone.0281159. (2023).
108 Caputo, E., Mandrich, L. SARS-CoV-2: Searching for the Missing Variants. Viruses 14, 2364. doi: 2310.3390/v14112364. (2022).
109 Zappa, M., Verdecchia, P, Angeli, F. Knowing the new Omicron BA.2.75 variant ('Centaurus'): A simulation study. Eur J Intern Med 105, 107-108. doi: 110.1016/j.ejim.2022.1008.1009. (2022).
110 Sabbatucci, M., Vitiello, A, Clemente, S, Zovi, A, Boccellino, M, Ferrara, F, Cimmino, C, Langella, R, Ponzo, A, Stefanelli, P, Rezza, G. . Omicron variant evolution on vaccines and monoclonal antibodies. Inflammopharmacology 31, 1779-1788 . doi: 1710.1007/s10787-10023-01253-10786 (2023).
111 Fernandes, Q., Inchakalody, VP, Merhi, M, Mestiri, S, Taib, N, Moustafa, Abo El-Ella, D, Bedhiafi, T, Raza, A, Al-Zaidan, L, Mohsen, MO, Yousuf Al-Nesf, MA, Hssain, AA, Yassine, HM, Bachmann, MF, Uddin, S, Dermime, S. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med 54, 524-540 (2022).
112 Dechecchi, M., Tamanini, A, Bonizzato, A, Cabrini, G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 268, 382-390 (2000).
113 Lerch, T., Chapman, MS. . Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). . Virology 423, 6-13 (2012).
114 Qiu, J., Handa, A, Kirby, M, Brown, KE. . The interaction of heparin sulfate and adeno-associated virus 2. Virology 269, 137-147 (2000).
115 Murakami, S., Takenaka-Uema, A, Kobayashi,T, Kato, K, Shimojima, M, Palmarini, M, Horimoto, T. Heparan Sulfate Proteoglycan Is an Important Attachment Factor for Cell Entry of Akabane and Schmallenberg Viruses. J Virol 91, pii: e00503-00517 (2017).
116 McAllister , N., Liu, Y, Silva, LM, Lentscher, AJ, Chai, W, Wu, N, Griswold, KA, Raghunathan, K, Vang, L, Alexander ,J, Warfield, KL, Diamond, MS, Feizi,T, Silva, LA, Dermody, TS. Chikungunya Virus Strains from Each Genetic Clade Bind Sulfated Glycosaminoglycans as Attachment Factors. J Virol 94, e01500-01520. (2020).
117 Merilahti, P., Karelehto, E, Susi, P. Role of Heparan Sulfate in Cellular Infection of Integrin-Binding Coxsackievirus A9 and Human Parechovirus 1 Isolates. . PLoS One 11, e0147168 (2016).
118 Pourianfar , H., Kirk, K, Grollo, L. Initial evidence on differences among Enterovirus 71, Coxsackievirus A16 and Coxsackievirus B4 in binding to cell surface heparan sulphate. Virusdisease 25, 277-284 (2014).
119 Zautner, A., Jahn, B, Hammerschmidt, E, Wutzler, P, Schmidtke, M. N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J Virol 80, 6629-6636 (2006).
120 Artpradit, C., Robinson, LN, Gavrilov, BK, Rurak, TT, Ruchirawat, M, Sasisekharan, R. Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles. Virus Res 176, 69-77 (2013).
121 Hilgard, P., Stockert, R. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 32, 1069-1077 (2000).
122 Saksono, B., Dewi, BE, Nainggolan, L, Suda, Y. A Highly Sensitive Diagnostic System for Detecting Dengue Viruses Using the Interaction between a Sulfated Sugar Chain and a Virion. PLoS One 10, e0123981 (2015).
123 Wu, S., Wu, Z, Wu, Y, Wang, T, Wang, M, Jia, R, Zhu, D, Liu, M, Zhao, X, Yang, Q, Wu, Y, Zhang, S, Liu, Y, Zhang, L, Yu, Y, Pan, L, Chen, S, Cheng, A. . Heparin sulfate is the attachment factor of duck Tembus virus on both BHK21 and DEF cells. Virol J 16, 134 (2019).
124 Tamhankar, M., Gerhardt, DM, Bennett, RS, Murphy, N, Jahrling, PB, Patterson, JL. Heparan sulfate is an important mediator of Ebola virus infection in polarized epithelial cells. Virol J 15, 135 (2018).
125 Israelsson, S., Gullberg, M, Jonsson, N, Roivainen, M, Edman, K, Lindberg, AM. Studies of Echovirus 5 interactions with the cell surface: heparan sulfate mediates attachment to the host cell. Virus Res 151, 170-176 (2010).
126 Tan, C., Poh, CL, Sam, IC, Chan, YF. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. . J Virol 87, 611-620 (2013).
127 Tan, C., Sam, IC, Lee, VS, Wong, HV, Chan, YF. VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology 501, 79-87 (2017).
128 Salvador, B., Sexton, NR, Carrion, R Jr, Nunneley, J, Patterson, JL, Steffen, I, Lu, K, Muench, MO, Lembo, D, Simmons, G. . Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol 87, 3295-3304 (2013).
129 Mathieu, C., Dhondt, KP, Châlons, M, Mély, S, Raoul, H, Negre, D, Cosset, FL, Gerlier, D, Vivès, RR, Horvat, B. Heparan sulfate-dependent enhancement of henipavirus infection. mBio 6, e02427 (2015).
130 Schulze, A., Gripon, P, Urban, S. . Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 16, 1759-1766 (2007).
131 Lamas Longarela, O., Schmidt, TT, Schöneweis, K, Romeo, R, Wedemeyer, H, Urban, S, Schulze, A. P. Proteoglycans act as cellular hepatitis delta virus attachment receptors. . PLoS One 8, e58340 (2013).
132 Olenina, L., Kuzmina, TI, Sobolev, BN, Kuraeva, TE, Kolesanova, EF, Archakov, AI. . Identification of glycosaminoglycan-binding sites within hepatitis C virus envelope glycoprotein E2. . J Viral Hepat 12, 584-593 (2005).
133 Xu, Y., Martinez, P, Séron, K, Luo, G, Allain, F, Dubuisson, J, Belouzard, S. Characterization of hepatitis C virus interaction with heparan sulfate proteoglycans. J Virol 89, 3846-3858 (2015).
134 Akula, S., Pramod, NP, Wang, FZ, Chandran, B. Human herpesvirus 8 envelope-associated glycoprotein B interacts with heparan sulfate-like moieties. Virology 284, 235-249 (2001).
135 Feyzi, E., Trybala, E, Bergström, T, Lindahl, U, Spillmann, D. . Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C. J Biol Chem 372, 24850-24857 (1997).
136 Thammawat, S., Sadlon, TA, Hallsworth, PG, Gordon, DL. . Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection. J Virol 82, 11767-11774 (2008).
137 Karasneh, G., Ali,M, Shukla, D. . An important role for syndecan-1 in herpes simplex virus type-1 induced cell-to-cell fusion and virus spread. PLoS One 6, e25252 (2011).
138 Terry-Allison, T., Montgomery, RI, Warner, MS, Geraghty, RJ, Spear, PG. Contributions of gD receptors and glycosaminoglycan sulfation to cell fusion mediated by herpes simplex virus 1. Virus Res 74, 39-45 (2001).
139 Connell, B. a. L.-J., H. Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibition. Frontiers in Immunology 4, 385 (2013).
140 Guibinga, G., Miyanohara, A, Esko, JD, Friedmann, T. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther 5, 538-546 (2002).
141 Trkola, A., Gordon, C, Matthews, J, Maxwell, E, Ketas, T, Czaplewski ,L, Proudfoot, AE, Moore, JP. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. J Virol 73, 6370-6379 (1999).
142 Nasimuzzaman, M., Persons, DA. Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells. Mol Ther. 2012 Jun;20(6):1158-66. Cell Membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells. Mol Ther 20, 1158-1166 (2012).
143 Plochmann, K., Horn, A, Gschmack, E, Armbruster, N, Krieg, J, Wiktorowicz, T, Weber, C, Stirnnagel, K, Lindemann, D, Rethwilm, A, Scheller, C. Heparan sulfate is an attachment factor for foamy virus entry. J Virol 86, 10028-10035 (2012).
144 Bousarghin, L., Hubert, P, Franzen, E, Jacobs, N, Boniver, J, Delvenne, P. Human papillomavirus 16 virus-like particles use heparan sulfates to bind dendritic cells and colocalize with langerin in Langerhans cells. J Gen Virol 86, 1297-1305 (2005).
145 Feldman, S., Audet, S, Beeler, JA. . The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol 74, 6442-6447 (2000).
146 Chang, A., Masante, C, Buchholz, UJ, Dutch, RE. Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. J Virol 86, 3230-3243 (2012).
147 Su, C., Liao, CL, Lee, YL, Lin, YL. Highly sulfated forms of heparin sulfate are involved in japanese encephalitis virus infection. Virology 286, 206-215 (2001).
148 Chowalter, R., Pastrana, DV, Buck, CB. Glycosaminoglycans and sialylated glycans sequentially facilitate Merkel cell polyomavirus infectious entry. PLoS Pathog 7, e1002161 (2011).
149 Kureishy, N., Faruque, D, Porter, CD. Primary attachment of murine leukaemia virus vector mediated by particle-associated heparan sulfate proteoglycan. Biochem J 400, 421-430 (2006).
150 Gillet , L., Adler, H, Stevenson ,PG. Glycosaminoglycan interactions in murine gammaherpesvirus-68 infection. PLoS One 2, e347 (2007).
151 Huan, C., Wang, Y, Ni, B, Wang, R, Huang, L, Ren, XF, Tong, GZ, Ding, C, Fan, HJ, Mao, X. Porcine epidemic diarrhea virus uses cell-surface heparan sulfate as an attachment factor. . Arch Virol 160, 1621-1628 (2015).
152 Trybala, E., Bergström, T, Spillmann, D, Svennerholm, B, Olofsson, S, Flynn, SJ, Ryan, P. Mode of interaction between pseudorabies virus and heparan sulfate/ heparin. Virology 218, 35-42 (1996).
153 Sasaki, M., Anindita, PD, Ito, N, Sugiyama, M, Carr, M, Fukuhara, H, Ose, T, Maenaka, K, Takada, A, Hall, WW, Orba, Y, Sawa, H. The Role of Heparan Sulfate Proteoglycans as an Attachment Factor for Rabies Virus Entry and Infection. J Infect Dis 217, 1740-1749 (2018).
154 Hallak, L., Spillmann, D, Collins, PL, Peeples, ME. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 74, 10508-10513 (2000).
155 Shields, B., Mills, J, Ghildyal, R, Gooley, P, Meanger, J. Multiple heparin binding domains of respiratory syncytial virus G mediate binding to mammalian cells. Arch Virol 148, 1987-2003 (2003).
156 Ennemoser, M., Rieger, J, Muttenthaler, E, Gerlza, T, Zatloukal, K, Kungl, AJ. Enoxaparin and pentosan polysulfate bind to the SARS-CoV-2 spike protein and human ACE2 receptor, inhibiting Vero cell infection. Biomedicines 10, 49 (2022).
157 Escribano-Romero, E., Jimenez-Clavero, MA, Gomes, P, García-Ranea, JA, Ley, V. Heparan sulphate mediates swine vesicular disease virus attachment to the host cell. J Gen Virol 85, 653-663 (2004).
158 Byrnes, A., Griffin, DE. Binding of Sindbis virus to cell surface heparan sulfate. J Virol 72, 7349-7356 (1998).
159 Hulst, M., van Gennip, HG, Moormann, RJ. . Passage of classical swine fever virus in cultured swine kidney cells selects virus variants that bind to heparan sulfate due to a single amino acid change in envelope protein E(rns). J Virol 74, 9553-9561 (2000).
160 Luteijn, R., van Diemen, F, Blomen, VA, Boer, IGJ, Manikam Sadasivam, S, van Kuppevelt, TH, Drexler, I, Brummelkamp, TR, Lebbink, RJ, Wiertz, EJ. . A Genome-Wide Haploid Genetic Screen Identifies Heparan Sulfate-Associated Genes and the Macropinocytosis Modulator TMED10 as Factors Supporting Vaccinia Virus Infection. J Virol 93, e02160-02118 (2019).
161 Tan, C., Sam, IC, Chong, WL, Lee, VS, Chan, YF. Polysulfonate suramin inhibits Zika virus infection. Antiviral Res 143, 186-194 (2017).
162 García-Villalón, D., Gil-Fernández, C. . Antiviral activity of sulfated polysaccharides against African swine fever virus. Antiviral Res 15, 139-148 (1991).
163 Baba, M., Snoeck, R, Pauwels, R, de Clercq, E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 32, 1742-1745 (1988).
164 Baba, M., Nakajima, M, Schols, D, Pauwels, R, Balzarini, J, De Clercq, E. . Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res 9, 335-343 (1988).
165 Ma, G., Yasunaga, JI, Ohshima, K, Matsumoto, T, Matsuoka, M. Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 Activities In Vitro and In Vivo. J Virol 93, e00413-00419 (2019).
166 Herrero, L., Foo, SS, Sheng, KC, Chen, W, Forwood, MR, Bucala, R, Mahalingam, S. Pentosan Polysulfate: a Novel Glycosaminoglycan-Like Molecule for Effective Treatment of Alphavirus -Induced Cartilage Destruction and Inflammatory Disease. J Virol 89, 8063-8076 (2015).
167 Krishnan, R., Duiker, M, Rudd, PA, Skerrett, D, Pollard, JGD, Siddel, C, Rifat, R, Ng, JHK, Georgius, P, Hererro, LJ, Griffin, P. Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study. BMC Musculoskelet Disord 22, 271 (2021).
168 Tavares-Júnior, J., de Souza, ACC, Borges, JWP, Oliveira, DN, Siqueira-Neto, JI, Sobreira-Neto, MA, Braga-Neto, P. COVID-19 associated cognitive impairment: A systematic review. . Cortex 152, 77-97 (2022).
169 Kumagai, K., Shirabe, S, Miyata, N, Murata, M, Yamauchi, A, Kataoka, Y, Niwa, M. Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis--an open clinical trial. BMC Clin Pharmacol 10, 7. doi: 10.1186/1472-6904-1110-1187. (2010).
170 Eita, M., Ashour, RH, El-Khawaga, OY. . Pentosan polysulfate exerts anti-inflammatory effect and halts albuminuria progression in diabetic nephropathy: Role of combined losartan. . Fundam Clin Pharmacol 36, 801-810. doi: 810.1111/ fcp.12781 (2022).
171 Rudd, P., Lim, EXY, Stapledon, CJM, Krishnan, R, Herrero, LJ. Pentosan polysulfate sodium prevents functional decline in chikungunya infected mice by modulating growth factor signalling and lymphocyte activation. PLoS ONE 16, e0255125 (2021).
172 Krishnan, R., Stapledon, CJM, Mostafavi, H, Freitas, JR, Liu, X, Mahalingam, S, Zaid, A. Anti-inflammatory actions of Pentosan polysulfate sodium in a mouse model of influenza virus A/PR8/34-induced pulmonary inflammation. Front Immunol 14, 1030879. doi: 1030810.103338 9/fimmu.1032023.1030879 (2023).
173 Bertini, S., Alekseeva, A, Elli, S, Pagani, I, Zanzoni, S, Eisele, G, Krishnan, R, Maag, KP, Reiter, C, Lenhart, D, Gruber, R, Yates, EA, Vicenzi, E, Naggi, A, Bisio, A, Guerrin,i M. Pentosan Polysulfate Inhibits Attachment and Infection by SARS-CoV-2 In Vitro: Insights into Structural Requirements for Binding. . Thromb Haemost 122, 984-997. doi: 910.1055/a-1807-0168 (2022).
174 Wool, G., Miller, JL. . The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology 88, 15-27, doi:doi: 10.1159/000512007. (2021).
175 Iba, T., Levy, JH, Levi ,M, Thachil, J. Coagulopathy in COVID-19. J Thromb Haemost 18, 2103-2109, doi:doi: 10.1111/jth.14975 (2020).
176 Grobler, C., Maphumulo, SC, Grobbelaar, LM, Bredenkamp, JC, Laubscher, GJ, Lourens, PJ, Steenkamp, J, Kell, DB, Pretorius, E. Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes. Int J Mol Sci 21, 5168, doi: doi: 10.3390/ijms21145168. (2020).
177 Vögtle, T., Sharma, S, Mori, J, Nagy, Z, Semeniak, D, Scandola, C, Geer, MJ, Smith, CW, Lane, J, Pollack, S, Lassila, R, Jouppila, A, Barr, AJ, Ogg, DJ, Howard, TD, McMiken, HJ, Warwicker, J, Geh C, Rowlinson, R, Abbott ,WM, Eckly, A, Schulze, H, Wright ,GJ, Mazharian, A, Fütterer, K, Rajesh, S, Douglas, MR, Senis, YA. Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B. . Elife 8, e46840 (2019).
178 Koupenova, M., Corkrey, HA, Vitseva, O, Tanriverdi, K, Somasundaran, M, Liu, P, Soofi, S, Bhandari, R, Godwin, M, Parsi, KM, Cousineau, A, Maehr, R, Wang, JP, Cameron, SJ, Rade, J, Finberg, RW, Freedman, JE. SARS-CoV-2 Initiates Programmed Cell Death in Platelets. Circ Res 129, 631-646 (2021).
179 Lord, M., Tang, F, Rnjak-Kovacina, J, Smith, JGW, Melrose, J, Whitelock ,JM. . The multifaceted roles of perlecan in fibrosis. . Matrix Biol 68-69, 150-166 (2018).
180 Lord, M., Chuang, CY, Melrose, J, Davies, MJ, Iozzo, RV, Whitelock, JM. . The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling. Matrix Biol 35, 112-122 (2014).
181 Whitelock, J., Melrose, J, Iozzo ,RV. Diverse cell signaling events modulated by perlecan. Biochemistry 47, 11174-11183 (2008).
182 Hayashida, K., Aquino, RS, Park, PW. Coreceptor functions of cell surface heparan sulfate proteoglycans. Am J Physiol Cell Physiol 322, C896-C912 (2022).
183 Smits , N., Shworak ,NW, Dekhuijzen, PN, van Kuppevelt ,TH. Heparan sulfates in the lung: structure, diversity, and role in pulmonary emphysema. Anat Rec (Hoboken) 293, 955-967 (2010).
184 Burgess, J., Mauad, T, Tjin, G, Karlsson, JC, Westergren-Thorsson, G. The extracellular matrix - the under-recognized element in lung disease? J Pathol 240, 397-409 (2016).
185 Burgstaller, G., Oehrle, B, Gerckens, M, White, ES, Schiller, HB, Eickelberg, O. The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. . Eur Respir J 50, 1601805 (2017).
186 Zhou, Y., Horowitz ,JC, Naba, A, Ambalavanan, N, Atabai,, K, Balestrini J, Bitterman, PB, Corley, RA, Ding, BS, Engler, AJ, Hansen, KC, Hagood, JS, Kheradmand, F, Lin, QS, Neptune, E, Niklason, L, Ortiz, LA, Parks, WC, Tschumperlin, DJ, White, ES, Chapman, HA, Thannickal, VJ. . Extracellular matrix in lung development, homeostasis and disease. Matrix Biol 73, 77-104 (2018).
187 Hackett, T., Ose,i ET. Modeling Extracellular Matrix-Cell Interactions in Lung Repair and Chronic Disease. Cells 10, 2145 (2021).
188 Phogat, S., Thiam, F, Al Yazeedi, S, Abokor, FA, Osei, ET. 3D in vitro hydrogel models to study the human lung extracellular matrix and fibroblast function. Respir Res 24, 242 (2023).
189 Ma, H., Wu, X, Li ,Y, Xia, Y. . Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis. Front Pharmacol 13, 963054 (2022).
190 Patel, D., Snelgrove, RJ. The multifaceted roles of the matrikine Pro-Gly-Pro in pulmonary health and disease. Eur Respir Rev 27, 180017 (2018).
191 Burgess, J., Weckmann, M. Matrikines and the lungs. Pharmacol Ther 134, 317-337 (2012).
192 Gressett , T., Hossen, ML, Talkington, G, Volic, M, Perez, H, Tiwari, PB, Chapagain, P, Bix, G. Molecular interactions between perlecan LG3 and the SARS-CoV-2 spike protein receptor binding domain. Protein Sci 33, e4843 (2024).
193 Lavorgna, T., Gressett, TE, Chastain, WH, Bix, GJ. . Perlecan: a review of its role in neurologic and musculoskeletal disease. Front Physiol 14, 1189731 (2023).
194 Hayes, A., Farrugia, BL, Biose, IJ, Bix, GJ, Melrose, J. Perlecan, A Multi-Functional, Cell-Instructive, Matrix-Stabilizing Proteoglycan With Roles in Tissue Development Has Relevance to Connective Tissue Repair and Regeneration. Front Cell Dev Biol 10, 856261 (2022).
195 Kunnathattil, M., Rahul, P, Skaria, T. Soluble vascular endothelial glycocalyx proteoglycans as potential therapeutic targets in inflammatory diseases. . Immunol Cell Biol 102, 97-116 (2024).
196 Yoshida, H., Nagaoka, A, Kusaka-Kikushima, A, Tobiishi, M, Kawabata, K, Sayo, T, Sakai, S, Sugiyama, Y, Enomoto, H, Okada, Y, Inoue, S. KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization. Proc Natl Acad Sci U S A 110, 5612-5617 (2013).
197 Shimizu, H., Shimoda, M, Mochizuki, S, Miyamae, Y, Abe, H, Chijiiwa, M, Yoshida, H, Shiozawa, J, Ishijima, M, Kaneko, K, Kanaji, A, Nakamura, M, Toyama, Y, Okada, Y. Hyaluronan-Binding Protein Involved in Hyaluronan Depolymerization Is Up-Regulated and Involved in Hyaluronan Degradation in Human Osteoarthritic Cartilage. Am J Pathol 188, 2109-2119 (2018).
198 Song, Y., He, P, Rodrigues, AL, Datta, P, Tandon, R, Bates, JT, Bierdeman, MA, Chen, C, Dordick, J, Zhang, F, Linhardt, RJ. . Anti-SARS-CoV-2 Activity of Rhamnan Sulfate from Monostroma nitidum. Mar Drugs 19, 685 (2021).
199 Koumpa, F., Forde, CT, Manjaly, JG. Sudden irreversible hearing loss post COVID-19. BMJ Case Rep 13, e238419 (2020).
200 Francis, D., Hutadilok, N, Kongtawelert, P, Ghosh, P. Pentosan polysulphate and glycosaminoglycan polysulphate stimulate the synthesis of hyaluronan in vivo. Rheumatol Int 13, 61-64 (1993).
201 Shen, B., Shimmon, S, Smith, MM, Ghosh, P. Biosensor analysis of the molecular interactions of pentosan polysulfate and of sulfated glycosaminoglycans with immobilized elastase, hyaluronidase and lysozyme using surface plasmon resonance (SPR) technology. J Pharm Biomed Anal 31, 83-93. doi: 10.1016/s0731-7085(1002)00606-00604. (2003).
202 Slevin, M., Krupinski, J, Gaffney, J, Matou, S, West ,D, Delisser, H, Savani, RC, Kumar, S. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol 26, 58-68 (2007).
203 Genasetti, A., Vigetti, D, Viola, M, Karousou, E, Moretto, P, Rizzi, M, Bartolini, B, Clerici,M, Pallotti, F, De Luca, G, Passi, A. Hyaluronan and human endothelial cell behavior. Connect Tissue Res 49, 120-123 (2008).
204 Matou-Nasri, S., Gaffney, J, Kumar, S, Slevin, M. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin. Int J Oncol 35, 761-773 (2009).
205 Slevin, M., Krupinski, J, Kumar, S, Gaffney, J. Angiogenic oligosaccharides of hyaluronan induce protein tyrosine kinase activity in endothelial cells and activate a cytoplasmic signal transduction pathway resulting in proliferation. Lab Invest 78, 987-1003 (1998).
206 Wang, Y., Cao, ML, Liu, YW, He, YQ, Yang, CX, Gao, F. CD44 mediates oligosaccharides of hyaluronan-induced proliferation, tube formation and signal transduction in endothelial cells. Exp Biol Med (Maywood) 236, 84-90 (2011).
207 Castor, C., Fremuth, TD, Furlong, AM, Jourdian, GW. Hyaluronic acid and proteoglycan synthesis by lung fibroblasts in basal and activated states. In Vitro 19, 462-470 (1983).
208 Ambrosino, P., Calcaterra, IL, Mosella, M, Formisano, R, D'Anna, SE, Bachetti, T, Marcuccio, G, Galloway, B, Mancini, FP, Papa, A, Motta, A, Di Minno, MND, Maniscalco, M. Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target. Biomedicines 10, 812 (2022).
209 Liu, N., Long, H, Sun, J, Li, H, He, Y, Wang, Q, Pan, K, Tong, Y, Wang, B, Wu, Q, Gong, L. New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression. J Med Virol 94, 3112-3120 (2022).
210 Robles, J., Zamora, M, Adan-Castro, E, Siqueiros-Marquez, L, Martinez de la Escalera, G, Clapp, C. The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB signaling. J Biol Chem 298, 101695 (2022).
211 Sbirkov, Y., Dzharov, V, Todorova, K, Hayrabedyan, S, Sarafian, V. Endothelial inflammation and dysfunction in COVID-19. Vasa 51, 62-70. doi: 10.1024/0301-1526/a000991. (2022).
212 Smith, M., Melrose, J. Xylan Prebiotics and the Gut Microbiome Promote Health and Wellbeing: Potential Novel Roles for Pentosan Polysulfate. Pharmaceuticals (Basel) 15, 1151 (2022).
213 Al-Zahrani, A., Gajewski, JB. Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome. Can Urol Assoc J 5, 113-118 (2011).
214 Anderson, J., Edelman, J, Ghosh, P. Effects of pentosan polysulphate on peripheral blood leukocyte populations and mononuclear cell procoagulant activity in patients with osteoarthritis. Curr Therap Res 58, 93-107 (1997).
215 Nickel, J., Forrest, JB, Tomera, K, Hernandez-Graulau, J, Moon, TD, Schaeffer, AJ, Krieger, JN, Zeitlin, SI, Evans, RJ, Lama, DJ, Neal, DE Jr, Sant, GR. . Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. J Urol 173, 1252-1255 (2005).
216 Nickel, J., Barkin, J, Forrest ,J, Mosbaugh, PG, Hernandez-Graulau, J, Kaufman, D, Lloyd, K, Evans, RJ, Parsons, CL, Atkinson, LE; Elmiron Study Group. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 65, 654-658 (2005).
217 Nickel, J., Herschorn, S, Whitmore, KE, Forrest, JB, Hu, P, Friedman, AJ, Baseman, AS. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol 193, 857-862 (2015).
218 Senthil, D., Malini, MM, Varalakshmi, P. Sodium pentosan polysulphate--a novel inhibitor of urinary risk factors and enzymes in experimental urolithiatic rats.. Ren Fail 20, 573-580 (1998).
219 Wallius, B., Tidholm, AE. . Use of pentosan polysulphate in cats with idiopathic, non-obstructive lower urinary tract disease: a double-blind, randomised, placebo-controlled trial. J Feline Med Surg 11, 409-412 (2009).
220 Baggen, J., Vanstreels, E, Jansen, S, Daelemans, D. . Cellular host factors for SARS-CoV-2 infection. Nat Microbiol 6, 1219-1232 (2021).
221 Takizawa, M., Ohuchi, E, Yamanaka ,H, Nakamura, H, Ikeda, E, Ghosh, P, Okada, Y. Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. Arthritis Rheum 43, 812-820 (2000).
222 Takizawa, M., Yatabe, T, Okada, A, Chijiiwa, M, Mochizuk,i S, Ghosh, P, Okada, Y. Calcium pentosan polysulfate directly inhibits enzymatic activity of ADAMTS4 (aggrecanase-1) in osteoarthritic chondrocytes. FEBS Lett 582, 2945-2949 (2008).
223 Troeberg, L., Fushimi, K, Khokha, R, Emonard, H, Ghosh, P, Nagase, H. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J 22, 3515-3524 (2008).
224 Bwalya, E., Kim, S, Fang, J, Wijekoon, HMS, Hosoya, K, Okumura, M. Pentosan polysulfate inhibits IL-1β-induced iNOS, c-Jun and HIF-1α upregulation in canine articular chondrocytes. PLoS One 12, e0177144 (2017).
225 Daly, C., Ghosh, P, Zannettino, ACW, Badal, T, Shimmon, R, Jenkin, G, Oehme, D, Jain, K, Sher, I, Vais, A, Cohen, C, Chandra, RV, Goldschlager, T. Mesenchymal progenitor cells primed with pentosan polysulfate promote lumbar intervertebral disc regeneration in an ovine model of microdiscectomy. . Spine J 18, 491-506 (2018).
226 Kumagai, K., Shirabe, S, Miyata, N, Murata, M, Yamauchi, A, Kataoka, Y, Niwa, M. Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis--an open clinical trial. . BMC Clin Pharmacol 10, 7 (2010).
227 Oehme, D., Ghosh, P, Goldschlager, T, Itescu, S, Shimon, S, Wu, J, McDonald, C, Troupis, JM, Rosenfeld, JV, Jenkin, G. Reconstitution of degenerated ovine lumbar discs by STRO-3-positive allogeneic mesenchymal precursor cells combined with pentosan polysulfate. J Neurosurg Spine 24, 715-726 (2016).
228 Andrews, J., Ghosh, P, Lentini, A, Ternai, B. . The interaction of pentosan polysulphate (SP54) with human neutrophil elastase and connective tissue matrix components. Chem Biol Interact 47, 157-173 (1983).
229 Suranji Wijekoon, H., Kim, S, Bwalya, EC, Fang, J, Aoshima, K, Hosoya, K, Okumura, M. Anti-arthritic effect of pentosan polysulfate in rats with collagen-induced arthritis. Res Vet Sci 122, 179-185 (2019).
230 Frith, J., Cameron, AR, Menzies, DJ, Ghosh, P, Whitehead, DL, Gronthos, S, Zannettino, AC, Cooper-White, JJ. An injectable hydrogel incorporating mesenchymal precursor cells and pentosan polysulphate for intervertebral disc regeneration. Biomaterials 34, 9430-9440 (2013).
231 Frith, J., Menzies, DJ, Cameron, AR, Ghosh, P, Whitehead, DL, Gronthos, S, Zannettino, AC, Cooper-White, JJ. Effects of bound versus soluble pentosan polysulphate in PEG/HA-based hydrogels tailored for intervertebral disc regeneration. Biomaterials 35, 1150-1162 (2014).
232 Lohmann, N., Schirmer, L, Atallah, P, Wandel, E, Ferrer,RA, Werner, C, Simon, JC, Franz, S, Freudenberg, U. Glycosaminoglycan-based hydrogels capture inflammatory chemokines and rescue defective wound healing in mice. Sci Transl Med 9, pii: eaai9044 (2017).
233 Kilgore, K., Naylor, KB, Tanhehco, EJ, Park, JL, Booth, EA, Washington, RA, Lucchesi, BR. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated myocardial injury in the rabbit perfused heart. J Pharmacol Exp Ther 285, 987-994 (1998).
234 Klegeris, A., Singh, EA, McGeer, PL. . Effects of C-reactive protein and pentosan polysulphate on human complement activation. Immunology 106, 381-388 (2002).
235 Fischer, A., Barrowcliffe, TW, Thomas, DP. . A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation. Thromb Haemost 47, 104-108 (1982).
236 Giedrojć, J., Radziwon, P, Klimiuk, M, Bielawiec, M, Breddin, HK, Kłoczko, J. Experimental studies on the anticoagulant and antithrombotic effects of sodium and calcium pentosan polysulphate. J Physiol Pharmacol 50, 111-119 (1999).
237 Orme, C., Harris, RC. . A comparison of the lipolytic and anticoagulative properties of heparin and pentosan polysulphate in the thoroughbred horse. Acta Physiol Scand 59, 179-185 (1997).
238 Vinazzer, H. Effect of pentosan polysulfate on fibrinolysis: basic tests and clinical application. Semin Thromb Hemost 17, 375-378 (1991).
239 Goad, K., Horne, MK 3rd, Gralnick, HR. Pentosan-induced thrombocytopenia: support for an immune complex mechanism. Br J Haematol 88, 803-808 (1994).
240 Tardy-Poncet, B., Tardy, B, Grelac, F, Reynaud, J, Mismetti, P, Bertrand, JC, Guyotat, D. Pentosan polysulfate-induced thrombocytopenia and thrombosis. Am J Hematol 45, 252-257 (1994).
241 Verbruggen, G., Veys, EM. Intra-articular injection pentosan polysulphate results in increased hyaluronan molecular weight in joint fluid. Clin Exp Rheumatol 10, 249-254 (1992).
242 Stapledon, C., Tsangari, H, Solomon, LB, Campbell, DG, Hurtado, P, Krishnan, R, Atkins, GJ. Human osteocyte expression of Nerve Growth Factor: The effect of Pentosan Polysulphate Sodium (PPS) and implications for pain associated with knee osteoarthritis. PLoS One 14, e0222602 (2019).
243 Sampson, M., Kabbani, M, Krishnan, R, Nganga, M, Theodoulou, A, Krishnan, J. Improved clinical outcome measures of knee pain and function with concurrent resolution of subchondral Bone Marrow Edema Lesion and joint effusion in an osteoarthritic patient following Pentosan Polysulphate Sodium treatment: a case report. BMC Musculoskelet Disord 18, 396 (2017).
244 Pluda, J., Shay, LE, Foli, A, Tannenbaum, S, Cohen, PJ, Goldspiel, BR, Adamo, D, Cooper, MR, Broder, S, Yarchoan, R. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 85, 1585-1592 (1993).
245 Alberca, G., Solis-Castro, RL, Solis-Castro, ME, Alberca, RW. . Coronavirus disease-2019 and the intestinal tract: An overview. World J Gastroenterol 27, 1255-1266, doi:doi: 10.3748/wjg.v27.i13.1255. (2021).
246 He, F., Zhang, T, Xue, K, Fang, Z, Jiang, G, Huang, S, Li, K, Gu, Z, Shi, H, Zhang, Z, Zhu, H, Lin, L, Li, J, Xiao, F, Shan, H, Yan, R, Li, X, Yan, Z. . Fecal multi-omics analysis reveals diverse molecular alterations of gut ecosystem in COVID-19 patients. Anal Chim Acta 1180, 338881, doi:doi: 10.1016 /j.aca.2021.338881 (2021).
247 Zhang, B., Zhong, Y, Dong, D, Zheng, Z, Hu, J. Gut microbial utilization of xylan and its implication in gut homeostasis and metabolic response. Carbohydr Polym 286, 119271 (2022).
248 Lee JY, T. R., Bäumler AJ. The microbiome and gut homeostasis. Science 377, eabp9960 (2022).
249 Xiao, Z., Pan, M, Li, X, Zhao, C. Impact of SARS-CoV2 infection on gut microbiota dysbiosis. Microbiome Res Rep 3, 7 (2023).
250 Nordberg Karlsson, E., Schmitz, E, Linares-Pastén, JA, Adlercreutz, P. Endo-xylanases as tools for production of substituted xylooligosaccharides with prebiotic properties. Appl Microbiol Biotechnol 102, 9081-9088 (2018).
251 Zhang, M., Chekan, JR, Dodd, D, Hong, PY, Radlinski, L, Revindran, V, Nair, SK, Mackie, RI, Cann, I. Xylan utilization in human gut commensal bacteria is orchestrated by unique modular organization of polysaccharide-degrading enzymes. Proc Natl Acad Sci U S A. 111, E3708-3717 (2014).
252 Childs, C., Röytiö, H, Alhoniemi, E, Fekete, AA, Forssten, SD, Hudjec, N, Lim, YN, Steger ,CJ, Yaqoob, P, Tuohy, KM, Rastall, RA, Ouwehand, AC, Gibson, GR. Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalis subsp. lactis induce bifidogenesis and modulate markers of immune function in healthy adults: a double-blind, placebo-controlled, randomised, factorial cross-over study. Br J Nutr 111, 1945-1956 (2014).
253 Gesaka, S., Obimbo, MM, Wanyoro, A. . Coronavirus disease 2019 and the placenta: A literature review. Placenta 126, 209-223 (2022).
254 Ojha, R., Gurjar, K, Ratnakar, TS, Mishra, A, Prajapati, VK. . Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. Hum Immunol 83, 346-355 (2022).
255 Chaves-Medina, M., Gómez-Ospina, JC, García-Perdomo, HA. . Molecular mechanisms for understanding the association between TMPRSS2 and beta coronaviruses SARS-CoV-2, SARS-CoV and MERS-CoV infection: scoping review. Arch Microbiol 204, 77 (2021).
256 Jacobs, J., Booth, GS. COVID-19 and Immune-Mediated RBC Destruction. Am J Clin Pathol 157, 844-851 (2022).
257 Wendisch, D., Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, Chua RL, Knoll R, Timm S, Brumhard S, Krammer T, Zauber H, Hiller AL, Pascual-Reguant A, Mothes R, Bülow RD, Schulze J, Leipold AM, Djudjaj S, Erhard F, Geffers R, Pott F, Kazmierski J, Radke J, Pergantis P, Baßler K, Conrad C, Aschenbrenner AC, Sawitzki B, Landthaler M, Wyler E, Horst D; Deutsche COVID-19 OMICS Initiative (DeCOI), Hippenstiel S, Hocke A, Heppner FL, Uhrig A, Garcia C, Machleidt F, Herold S, Elezkurtaj S, Thibeault C, Witzenrath M, Cochain C, Suttorp N, Drosten C, Goffinet C, Kurth F, Schultze JL, Radbruch H, Ochs M, Eils R, Müller-Redetzky H, Hauser AE, Luecken MD, Theis FJ, Conrad C, Wolff T, Boor P, Selbach M, Saliba AE, Sander LE. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell 184, 6243-6261.e6227 (2021).
258 Acharya, Y., Alameer, A, Calpin, G, Alkhattab, M, Sultan, S. . A comprehensive review of vascular complications in COVID-19. J Thromb Thrombolysis 53, 586-593 (2022).
259 Veizades, S., Tso, A, Nguyen, PK. . Infection, inflammation and thrombosis: a review of potential mechanisms mediating arterial thrombosis associated with influenza and severe acute respiratory syndrome coronavirus 2. Biol Chem 403, 231-241 (2021).
260 Plášek, J., Gumulec, J, Máca, J, Škarda, J, Procházka, V, Grézl, T, Václavík, J. COVID-19 associated coagulopathy: Mechanisms and host-directed treatment. Am J Med Sci 363, 465-475 (2022).
261 Rizal, S., Joshi, BR, Regmi, S. . Raised D-dimer Level among COVID-19 Patients in a Tertiary Care Hospital: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc 60, 259-262 (2022).
262 Al-Kuraishy, H., Al-Gareeb, AI, Kaushik, A, Kujawska, M, Batiha, GE. Hemolytic anemia in COVID-19. Ann Hematol 101, 1887-1895 (2022).
263 Wagener, F., Pickkers,, P, Peterson SJ, Immenschuh, S, Abraham, NG. Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections.. Antioxidants (Basel) 9, 540 (2020).
264 Ousaka, D., Nishibori, M. Is hemolysis a novel therapeutic target in COVID-19? Front Immunol 13, 956671 (2022).
265 Natale, N., Lukens, JR, Petri, WA Jr. The nervous system during COVID-19: Caught in the crossfire. Immunol Rev doi: 10.1111/imr.13114. (2022).
266 Valdes, E., Fuchs, B, Morrison, C, Charvet, L, Lewis, A, Thawani, S, Balcer, L, Galetta, SL, Wisniewski, T, Frontera, JA. Demographic and social determinants of cognitive dysfunction following hospitalization for COVID-19. J Neurol Sci 438, 120146 (2022).
267 Meyer , P., Hellwig, S, Blazhenets, G, Hosp, JA. Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review. J Nucl Med 63, 971-980 (2022).
268 Kao, J., Frankland, PW. COVID fog demystified. Cell S0092-8674, 00725-00725 (2022).
269 Maltezou, H., Pavli, A, Tsakris, A. . Post-COVID Syndrome: An Insight on Its Pathogenesis. Vaccines (Basel) 9, 497 (2021).
270 García-Grimshaw, M., Sankowski, R, Valdés-Ferrer, SI. . Neurocognitive and psychiatric post-coronavirus disease 2019 conditions: pathogenic insights of brain dysfunction following severe acute respiratory syndrome coronavirus 2 infection. Curr Opin Neurol 35, 375-383 (2022).
271 Anonymous. Long COVID and kids: more research is urgently needed. Nature 602, 183 (2022).
272 Ortona, E., Malorni, W. Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy. Eur Respir J 59, 2102245 (2022).
273 Schober, M., Robertson, CL, Wainwright, MS, Roa, JD, Fink, EL. COVID-19 and the Pediatric Nervous System: Global Collaboration to Meet a Global Need. Neurocrit Care 35, 283-290 (2021).
274 Deoni, S., Beauchemin, J, Volpe, A, Dâ Sa, V; RESONANCE Consortium. Impact of the COVID-19 Pandemic on Early Child Cognitive Development: Initial Findings in a Longitudinal Observational Study of Child Health. medRxiv [Preprint]. 08.10.21261846 (2021).
275 Dyer, O. Covid-19: Children born during the pandemic score lower on cognitive tests, study finds. BMJ. 2021 Aug 16;374:n2031. Dyer O. Covid-19: Children born during the pandemic score lower on cognitive tests, study finds. BMJ 374, n2031 (2021).
276 Ehrler, M., Werninger, I, Schnider, B, Eichelberger, DA, Naef,N, Disselhoff, V, Kretschmar, O, Hagmann, CF, Latal ,B, Wehrle, FM. Impact of the COVID-19 pandemic on children with and without risk for neurodevelopmental impairments. Acta Paediatr. 110, 1281-1288 (2021).
277 Liu, K., Howard, R, Banerjee, S, Comas-Herrera, A, Goddard, J, Knapp, M, Livingston, G, Manthorpe, J, O'Brien, JT, Paterson, RW, Robinson, L, Rossor, M, Rowe, JB, Sharp, DJ, Sommerlad, A, Suárez-González, A, Burns, A. Dementia wellbeing and COVID-19: Review and expert consensus on current research and knowledge gaps. Int J Geriatr Psychiatry 36, 1597-1639 (2021).
278 Hampshire, A., Trender, W, Chamberlain, SR, Jolly, AE, Grant, JE, Patrick, F, Mazibuko, N, Williams, SC, Barnby, JM, Hellyer, P, Mehta, MA. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine 39, 101044 (2021).
279 Palakshappa, J., Krall, JTW, Belfield, LT, Files, DC. Long-Term Outcomes in Acute Respiratory Distress Syndrome: Epidemiology, Mechanisms, and Patient Evaluation. Crit Care Clin 37, 895-911 (2021).
280 Schou, T., Joca, S, Wegener, G, Bay-Richter, C. Psychiatric and neuropsychiatric sequelae of COVID-19 - A systematic review. Brain Behav Immun 97, 328-348 (2021).
281 Yang, F., Zhao, H, Liu, H, Wu, X, Li, Y. . Manifestations and mechanisms of central nervous system damage caused by SARS-CoV-2. Brain Res Bull S0361-9230, 00284-00287 (2021).
282 Yong, S. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 53, 737-754 (2021).
283 Aiyegbusi, O., Hughes, SE, Turner, G, Rivera, SC, McMullan, C, Chandan, JS, Haroon, S, Price, G, Davies, EH, Nirantharakumar, K, Sapey, E, Calvert, MJ; TLC Study Group. Symptoms, complications and management of long COVID: a review. J R Soc Med 114, 428-442 (2021) (2021).
284 Chen, J., Zhang, W, Li, Y, Liu, C, Dong, T, Chen, H, et al Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor. Cell 188, 1729-1742.e1716. doi: 1710.10 16/j.cell.2025.1701.1042. (2025).
285 Srivastava, S., Sharma, D, Sridhar, SB, Kumar, S, Sahu, R, Ashique, S, et al HKU5-CoV-2: A silent threat looming in bats. Travel Med Infect Dis 65, 102838. doi: 102810.101016/j.tmaid.102025.102838. (2025).
286 Wang, N., Ji, W, Jiao, H, Veit ,M, Sun, J, Wang, Y, et al A MERS-CoV-like mink coronavirus uses ACE2 as an entry receptor. Nature 642, 739-746. doi: 710.1038/s41586-41025-09007-w. (2025).